

Andrew T. Berry
Jonathan M.H. Short
McCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
(973) 622-4444

Attorneys for Plaintiffs
AstraZeneca AB, Aktiebolaget Hässle,
AstraZeneca LP, KBI Inc. and KBI-E Inc.

Of Counsel:
Errol B. Taylor
Fredrick M. Zullow
John M. Griem, Jr.
MILBANK, TWEED, HADLEY &
& McCLOY LLP
1 Chase Manhattan Plaza
New York, New York 10005-1413
(212) 530-5000

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

ASTRAZENECA AB; AKTIEBOLAGET HÄSSLE; ASTRazeneca LP; KBI INC.; and KBI-E INC.,	:	Civil Action No. _____
Plaintiffs,	:	COMPLAINT FOR PATENT INFRINGEMENT
v.	:	AND CERTIFICATION PURSUANT TO LOCAL RULE 11.2
DR. REDDY'S LABORATORIES, LTD. and DR. REDDY'S LABORATORIES, INC.,	:	
Defendants.	:	

JURISDICTION AND VENUE

1. This is an action for patent infringement and a declaratory judgment arising under the Patent and Food and Drug laws of the United States, Titles 35 and 21, United States Code. Jurisdiction and venue are based on 28 U.S.C. §§ 1331, 1338(a), 1391(b), 1391(c), 1400(b), 2201, 2202 and 35 U.S.C. §§ 271(a), 271(b), 271(c), 271(e), 271(g).

2. On information and belief, Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (jointly and severally "DRL") have been and are engaging in activities directed toward infringement of United States Patent Nos. 5,714,504 (the "'504 patent"), 6,875,872 (the "'872 patent") and 6,369,085 (the "'085 patent"), by, *inter alia*, submitting an abbreviated new drug application designated ANDA No. 78-279 and by submitting Drug Master Files (DMF) seeking FDA's approval to manufacture commercially its proposed 20 mg and 40 mg product called "Esomeprazole Magnesium Delayed Release Capsules" (herein after referred to as "Esomeprazole Magnesium Capsules") containing the active ingredient esomeprazole magnesium.

3. In DRL's notice letter entitled "Notice of Paragraph IV Certification Re: Dr. Reddy's Laboratories, Ltd.'s and Dr. Reddy's Laboratories, Inc.'s Proposed Esomeprazole Magnesium Delayed Release Capsules; U.S. Patent Nos. 5,714,504, 6,875,872 and 5,877,192" (hereinafter referred to as the "Notice of Certification"), DRL has indicated that it intends to market its Esomeprazole Magnesium Capsules before the expiration of the '504 and '872 patents.

4. DRL's submission of ANDA No. 78-279 and the DMF, in addition to service of its Notice of Certification, indicates a refusal to change its current course of action.

5. There has been and is now an actual controversy between DRL and Plaintiffs as to whether DRL infringes the '504, '872, and '085 patents.

THE PARTIES

6. Plaintiff AstraZeneca AB is a company organized and existing under the laws of Sweden, having its principal place of business at Södertälje, Sweden. AstraZeneca AB was a corporate name change from Astra Aktiebolaget.

7. Plaintiff Aktiebolaget Hässle ("Hässle") is a company organized and existing under the laws of Sweden, having its principal place of business at Mölndal, Sweden.

8. Plaintiff AstraZeneca LP is a limited partnership organized under the laws of Delaware having its principal place of business at Wilmington, Delaware. AstraZeneca LP holds an approved New Drug Application from the United States Food and Drug Administration ("FDA") for an esomeprazole magnesium formulation which it sells under the name NEXIUM®.

9. Plaintiff KBI Inc. ("KBI") is a Delaware corporation having its principal place of business at Whitehouse Station, New Jersey.

10. Plaintiff KBI-E Inc. ("KBI-E") is a Delaware corporation, having its principal place of business at Wilmington, Delaware. KBI and KBI-E have exclusive rights in the United States to patents-in-suit.

11. On information and belief, defendant Dr. Reddy's Laboratories, Ltd. is a public limited liability company incorporated and existing under the laws of India and having a principal place of business at 7-1-27, Ameerpet, Hyderabad, 500 016, India.

12. On information and belief, defendant Dr. Reddy's Laboratories, Inc. is a New Jersey corporation, having its principal place of business at 200 Somerset Corporate Boulevard, Building II, 7th Floor, Bridgewater, NJ 08807.

13. On information and belief, Dr. Reddy's Laboratories, Inc. is a wholly owned subsidiary of Dr. Reddy's Laboratories, Ltd. and acts as the agent of Dr. Reddy's Laboratories, Ltd. in the United States.

14. On information and belief, Dr. Reddy's Laboratories Ltd., and Dr. Reddy's Laboratories, Inc. (jointly and severally "DRL") are doing business in New Jersey, have continuous and systematic contacts with New Jersey, have engaged in activities together related to the subject matter of this action and are subject to personal jurisdiction in this judicial district.

FIRST CLAIM FOR RELIEF: '504 PATENT

15. AstraZeneca AB, Hässle, AstraZeneca LP, KBI and KBI-E (collectively, "Plaintiffs") reallege paragraphs 1-14, above, as if set forth specifically here.

16. The '504 patent (copy attached as Exhibit "A"), entitled "Compositions," was issued on February 3, 1998 to Astra Aktiebolag upon assignment from the inventors Per Lennart Lindberg and Sverker Von Unge. The patent was subsequently assigned to AstraZeneca AB. The '504 patent claims, *inter alia*, pharmaceutical formulations comprising alkaline salts of esomeprazole (including esomeprazole magnesium) and methods of using esomeprazole magnesium.

17. Plaintiff AstraZeneca AB has been and is still the owner of the '504 patent. The '504 patent will expire on February 3, 2015 and pediatric exclusivity relating to the '504 patent expires on August 3, 2015.

18. DRL's Notice of Certification notified Plaintiffs that it had submitted an Abbreviated New Drug Application ("ANDA") to the FDA under 21 U.S.C. § 355(j), seeking the FDA's approval to manufacture, use, offer to sell and sell DRL's Esomeprazole Magnesium Capsules as a generic version of the NEXIUM® product.

19. In the Notice of Certification, DRL notified Plaintiffs that as part of its ANDA it had filed a certification of the type described in 21 U.S.C. § 355(j)(2)(A)(vii)(IV) ("Paragraph IV") with respect to the '504 patent. This statutory section requires, *inter alia*, certification by the ANDA applicant that the subject patent, here the '504 patent, "is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted . . ." The statute (21 U.S.C. § 355(j)(2)(B)(iv)) also requires a Paragraph IV notice to "include a detailed statement of the factual and legal basis of the applicant's opinion that the patent is not valid or will not be infringed." The FDA Rules and Regulations (21 C.F.R. § 314.95(c)) specify, *inter alia*, that a Paragraph IV notification must include "[a] detailed statement of the factual and legal basis of applicant's opinion that the patent is not valid, unenforceable, or will not be infringed." The detailed statement is to include "(i) [f]or each claim of a patent alleged not to be infringed, a full and detailed explanation of why the claim is not infringed" and "(ii) [f]or each claim of a patent alleged to be invalid or unenforceable, a full and detailed explanation of the grounds supporting the allegation."

20. On information and belief, at the time DRL's Notice of Certification was served, DRL was aware of the statutory provisions and regulations referred to in paragraph 19, above.

21. DRL's Notice of Certification, which is required by statute and regulation to provide a full and detailed explanation regarding non-infringement (see paragraph 19 above), does not allege non-infringement of all claims of the '504 patent.

22. DRL's Notice of Certification, which is required by statute and regulation to provide a full and detailed explanation regarding invalidity (see paragraph 19 above), does not allege invalidity of all claims of the '504 patent.

23. DRL's Notice of Certification, which is required by statute and regulation to provide a full and detailed explanation regarding unenforceability (see paragraph 19 above), does not address unenforceability or inequitable conduct of the '504 patent.

24. In the Notice of Certification, DRL did not provide the full and detailed statement required by, and therefore fails to comply with, the statutory and regulatory provisions set forth in paragraph 19, above, as to the '504 patent.

25. DRL's Notice of Certification fails to comply with the law, as specified in 21 U.S.C. § 355(j), and FDA rules and regulations, as specified in 21 C.F.R. § 314.95.

26. DRL has infringed the '504 patent under 35 U.S.C. § 271(e)(2) by filing its ANDA seeking approval from the FDA to engage in the commercial manufacture, use or sale of a drug claimed in this patent, or the use of which is claimed in this patent, prior to the expiration of the '504 patent.

27. On information and belief, DRL's Esomeprazole Magnesium Capsules, if approved, will be administered to human patients in a therapeutically effective amount to inhibit gastric acid secretion and for the treatment of gastrointestinal inflammatory disease. On information and belief, this administration will occur at DRL's active behest and

with its intent, knowledge and encouragement. On information and belief, DRL will actively encourage, aid and abet this administration with knowledge that it is in contravention of Plaintiffs' rights under the '504 patent.

28. On information and belief, DRL's Esomeprazole Magnesium Capsules are especially made or especially adapted to inhibit gastric acid secretion and for use in the treatment of gastrointestinal inflammatory disease via the administration of a therapeutically effective amount of a pharmaceutical formulation containing the claimed esomeprazole magnesium and a pharmaceutically acceptable carrier. On information and belief, DRL is aware that its Esomeprazole Magnesium Capsules are so made or so adapted. On information and belief, DRL is aware that its Esomeprazole Magnesium Capsules, if approved, will be used in contravention of Plaintiffs' rights under the '504 patent.

29. DRL's Notice of Certification does not allege and does not address non-infringement of claims 1-3, 5-7 and 10 of the '504 patent. By not addressing non-infringement of claims 1-3, 5-7 and 10 of the '504 patent in its Notice of Certification, DRL admits that its Esomeprazole Magnesium Capsules meet all limitations of claims 1-3, 5-7 and 10 of the '504 patent.

30. On information and belief, the manufacture, use and sale of DRL's Esomeprazole Magnesium Capsules infringe the '504 patent claims.

31. To further investigate whether DRL will infringe AstraZeneca's patents, in a letter dated December 11, 2007, AstraZeneca requested access to certain documents, information and samples, as well as access to DRL's ANDA No. 78-279 and the DMF.

32. DRL refused to agree to timely provide AstraZeneca sufficient access to all of the requested documents, information and samples and instead offered to produce only selected portions of DRL's ANDA No. 78-279 and certain finished product samples.

33. Plaintiffs bring this suit, in part, to employ the judicial process and the aid of discovery to obtain under appropriate judicial safeguards information to confirm that DRL's Esomeprazole Magnesium Capsules infringe the '504 patent claims including, but not limited to, claim 4 that DRL asserts is not infringed.

SECOND CLAIM FOR RELIEF: '872 PATENT

34. Plaintiffs reallege paragraphs 1-14 and 18, above, as if set forth specifically here.

35. The '872 patent, (copy attached as Exhibit "B"), entitled "Compounds," was issued on April 5, 2005 to AstraZeneca AB, upon assignment from the inventors Per Lennart Lindberg and Sverker Von Unge. The '872 patent claims, *inter alia*, esomeprazole magnesium salts.

36. Plaintiff AstraZeneca AB has been and still is the owner of the '872 patent. The '872 patent will expire on May 27, 2014 and pediatric exclusivity relating to the '872 patent expires on November 27, 2014.

37. In the Notice of Certification, DRL notified Plaintiffs that as part of its ANDA it had filed a certification of the type described in 21 U.S.C. § 355(j)(2)(A)(vii)(IV) ("Paragraph IV") with respect to the '872 patent. This statutory section requires, *inter alia*, certification by the ANDA applicant that the subject patent, here the '872 patent, "is invalid or will not be infringed by the manufacture, use, offer to sale or sale of the new drug for which the

application is submitted" The statute (21 U.S.C. § 355(j)(2)(B)(iv)) also requires a Paragraph IV notice to "include a detailed statement of the factual and legal basis of the applicant's opinion that the patent is not valid or will not be infringed." The FDA Rules and Regulations (21 C.F.R. § 314.95(c)) specify, *inter alia*, that a Paragraph IV notification must include "[a] detailed statement of the factual and legal basis of applicant's opinion that the patent is not valid, unenforceable, or will not be infringed." The detailed statement is to include "(i) [f]or each claim of a patent alleged not to be infringed, a full and detailed explanation of why the claim is not infringed" and "(ii) [f]or each claim of a patent alleged to be invalid or unenforceable, a full and detailed explanation of the grounds of supporting the allegation."

38. On information and belief, at the time DRL's Notice of Certification was served, DRL was aware of the statutory provisions and regulations referred to in paragraph 37, above.

39. DRL's Notice of Certification, which is required by statute and regulation to provide a full and detailed explanation regarding non-infringement (see paragraph 37 above), does not allege non-infringement of all the claims of the '872 patent.

40. DRL's Notice of Certification, which is required by statute and regulation to provide a full and detailed explanation regarding invalidity (see paragraph 37 above), does not allege invalidity of all the claims of the '872 patent.

41. DRL's Notice of Certification, which is required by statute and regulation to provide a full and detailed explanation regarding unenforceability (see paragraph 37 above), does not address unenforceability or inequitable conduct of the '872 patent.

42. In the Notice of Certification, DRL did not provide the full and detailed statement required by, and therefore fails to comply with, the statutory and regulatory provisions set forth in paragraph 37, above, as to the '872 patent.

43. DRL's Notice of Certification fails to comply with the law, as specified in 21 U.S.C. § 355(j), and FDA rules and regulations, as specified in 21 C.F.R. § 314.95.

44. DRL has infringed the '872 patent under 35 U.S.C. § 271(e)(2) by filing its ANDA seeking approval from the FDA to engage in the commercial manufacture, use or sale of a drug claimed in this patent, prior to the expiration of the '872 patent.

45. On information and belief, DRL's Esomeprazole Magnesium Capsules, if approved, will be administered to human patients at DRL's active behest and with its intent, knowledge and encouragement. On information and belief, DRL will actively encourage, aid and abet this administration with knowledge that it is in contravention of Plaintiffs' rights under the '872 patent.

46. On information and belief, DRL's Esomeprazole Magnesium Capsules are especially made or especially adapted for treatment of humans. On information and belief, DRL is aware that its Esomeprazole Magnesium Capsules are so made or so adapted. On information and belief, DRL is aware that its Esomeprazole Magnesium Capsules, if approved, will be used in contravention of Plaintiffs' rights under the '872 patent.

47. DRL's Notice of Certification does not allege and does not address non-infringement of claims 1, 2, 4, 5, 7, 8, 10 and 11 of the '872 patent. By not addressing non-infringement of claims 1, 2, 4, 5, 7, 8, 10 and 11 of the '872 patent in its Notice of Certification,

DRL admits that its Esomeprazole Magnesium Capsules meet all limitations in claims 1, 2, 4, 5, 7, 8, 10 and 11 of the '872 patent.

48. On information and belief, the manufacture, use and sale of DRL's Esomeprazole Magnesium Capsules infringe the '872 patent claims.

49. To further investigate whether DRL will infringe AstraZeneca's patents, in a letter dated December 11, 2007, AstraZeneca requested access to certain documents, information and samples, as well as access to DRL's ANDA No. 78-279 and the DMF.

50. DRL refused to agree to timely provide AstraZeneca sufficient access to all of the requested documents, information and samples and instead offered to produce only selected portions of DRL's ANDA No. 78-279 and certain finished product samples.

51. Plaintiffs bring this suit, in part, to employ the judicial process and the aid of discovery to obtain under appropriate judicial safeguards information to confirm that DRL's Esomeprazole Magnesium Capsules infringe the '872 patent claims including, but not limited to, claims 3, 6, 9, and 12 that DRL asserts are not infringed.

THIRD CLAIM FOR RELIEF: '085 PATENT

52. Plaintiffs reallege paragraphs 1-14 and 18, above, as if set forth specifically here.

53. The '085 patent, (copy attached as Exhibit "C"), entitled "Form of S-Omeprazole," was issued on April 9, 2002 to AstraZeneca AB, upon assignment from the inventors Hanna Cotton, Anders Kronström, Anders Mattson and Eva Möller. The '085 patent claims, *inter alia*, magnesium salts of esomeprazole trihydrate, pharmaceutical compositions

comprising the claimed salts, methods of treatment using the claimed salts, and processes for preparing the claimed salts.

54. Plaintiff AstraZeneca AB has been and still is the owner of the '085 patent. The '085 patent will expire on May 25, 2018 and pediatric exclusivity relating to the '085 patent expires on November 25, 2018.

55. DRL submitted to the FDA an Abbreviated New Drug Application, No. 78-279, seeking the FDA's approval to manufacture, use and sell DRL's proposed Esomeprazole Magnesium Capsules as a generic version of the NEXIUM® product.

56. On information and belief, DRL's Esomeprazole Magnesium Capsules will infringe the claims of the '085 patent.

57. To further investigate whether DRL will infringe AstraZeneca's patents, in a letter dated December 11, 2007, AstraZeneca requested access to certain documents, information and samples, as well as access to DRL's ANDA No. 78-279 and the DMF.

58. DRL refused to agree to timely provide AstraZeneca sufficient access to all of the requested documents, information and samples and instead offered to produce only selected portions of DRL's ANDA No. 78-279 and certain finished product samples.

59. DRL also refused to permit the use of any information to assess patents other than the '504, '872 and '192 patents.

60. Plaintiffs bring this suit, in part, to employ the judicial process and the aid of discovery to obtain under appropriate judicial safeguards information to confirm that the manufacture, use, offer to sell and sale of DRL's Esomeprazole Magnesium Capsules infringe AstraZeneca's patents.

WHEREFORE, Plaintiffs respectfully request the following relief:

- (a) A judgment declaring that the effective date of any approval of DRL's ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)) for the drug product "Esomeprazole magnesium" must be later than November 25, 2018, the expiration date of the last patent in suit, including pediatric exclusivity relating to the patent, that is infringed;
- (b) A judgment declaring that the '504, '872, and '085 patents remain valid, remain enforceable and have been infringed by defendant DRL;
- (c) A judgment declaring that DRL has not complied with the requirements of 35 U.S.C. § 271(e)(2), 21 U.S.C. § 355(j)(2)(A)(vii)(IV), 21 U.S.C. § 355(j)(2)(B)(iv), 21 C.F.R. § 314.94 and 21 U.S.C. § 314.95;
- (d) A permanent injunction against any infringement by DRL of the '504, '872, and '085 patents;
- (e) A judgment that DRL's conduct is exceptional;
- (f) Attorneys' fees in this action under 35 U.S.C. § 285;
- (g) Costs and expenses in this action; and
- (h) Such other relief as this Court may deem proper.

Respectfully Submitted,

Dated: January 17, 2008

By: S/Andrew T. Berry

Andrew T. Berry
Jonathan M.H. Short
McCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
(973) 622-4444

Attorneys for Plaintiffs
ASTRAZENECA AB,
AKTIEBOLAGET HÄSSLE,
ASTRAZENECA LP, KBI INC.
and KBI-E INC.

Of Counsel:
Errol B. Taylor
Fredrick M. Zullow
John M. Griem, Jr.
MILBANK, TWEED, HADLEY &
& McCLOY LLP
1 Chase Manhattan Plaza
New York, New York 10005-1413
(212) 530-5000

CERTIFICATION PURSUANT TO L. CIV. R. 11.2

Pursuant to Local Civil Rule 11.2, I hereby certify that the matter in controversy is the subject of the following action:

ASTRAZENECA AB; AKTIEBOLAGET HÄSSLE; ASTRAZENECA LP; KBI INC.; and KBI-E INC. v. RANBAXY PHARMACEUTICALS, INC., RANBAXY INC., RANBAXY LABORATORIES LTD., IVAX CORPORATION, IVAX PHARMACEUTICALS NV, INC., IVAX PHARMACEUTICALS, INC., TEVA PHARMACEUTICALS INDUSTRIES, LTD., TEVA PHARMACEUTICALS USA, ZENITH LABORATORIES, INC., 3:05-cv-05553-JAP-TJB (Consolidated) (District of New Jersey).

Dated: January 17, 2008

By: S/Andrew T. Berry
Andrew T. Berry
Jonathan M.H. Short
McCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
(973) 622-4444

Attorneys for Plaintiffs
ASTRAZENECA AB,
AKTIEBOLAGET HÄSSLE,
ASTRAZENECA LP, KBI INC.
and KBI-E INC.

Of Counsel:
Errol B. Taylor
Fredrick M. Zullow
John M. Griem, Jr.
MILBANK, TWEED, HADLEY &
& McCLOY LLP
1 Chase Manhattan Plaza
New York, New York 10005-1413
(212) 530-5000

EXHIBIT A



US005714504A

United States Patent [19]
Lindberg et al.

[11] **Patent Number:** **5,714,504**
[45] **Date of Patent:** **Feb. 3, 1998**

[54] COMPOSITIONS

- [75] Inventors: **Per Lennart Lindberg**, Mölndal;
Sverker Von Unge, Fjärås, both of
Sweden
- [73] Assignee: **Astra Aktiebolag**, Sodertalje, Sweden
- [21] Appl. No.: **376,512**
- [22] Filed: **Jan. 23, 1995**

Related U.S. Application Data

- [63] Continuation-in-part of Ser. No. 256,174, filed as PCT/
SE94/00509, May 27, 1994.

[30] Foreign Application Priority Data

May 28, 1993 [SE] Sweden 9301830

[51] Int. Cl. ⁶ C07D 401/12; A61K 31/44

[52] U.S. Cl. 514/338; 546/273.7

[58] Field of Search 546/273.7; 514/338

[56] References Cited**FOREIGN PATENT DOCUMENTS**

- 0005129 4/1981 European Pat. Off.
0124495 1/1987 European Pat. Off.
4035455 11/1990 Germany
4035455 5/1992 Germany

OTHER PUBLICATIONS

- Erlandsson et al., J. Chromatography, vol.532, pp. 305-319 (1990).
Cairns, et al. "Enantioselective HPLC determination . . ." Journal of Chromatography 8,666 (1995) 323-328.

Yamada et al. "Synthesis and isomerization of optical active . . ." Chem. Pharm. Bull. 42(8) (1994) 1679-1681.
K. Miwa et al. Jpn. Pharmacol. Ther. "Proton pump inhibitor in rats, mice and dogs" 18 (1990) 165-187 (transl).
H. Katsuki et al. "Determination of R(+)—and S(−)-Lansoprazole" Pharmaceutical Research 13(4) (1996) 611-615.
M. Tanaka et al. "Direct determination of pantoprazole enantiomers . . ." Anal. Chem. 68 (1996) 1513-1516.
P. Lindberg et al. "Omeprazole: The first proton pump inhibitor" Medicinal Res. Rev. 10 (1990) 2-50.
P. Lindberg et al. "The mechanism of action of . . . omeprazole" Journal of Medicinal Chemistry 29 (1986) 1327.

A. Brandstrom "Chemical reactions . . ." Reprint from Acta Chemica Scandinavica 43 (1989) 536-611.

K. Sigrist-Nelson et al. "Ro 18-5364, a potent inhibitor of the gastric (H⁺+K⁺)-ATPase" Eur. J. Bioch. 166 (1987) 453.

Polomomcoll et al. CA 117;90292. 1992.

Primary Examiner—Jane Fan

Attorney, Agent, or Firm—White & Case

[57] ABSTRACT

The novel optically pure compounds Na⁺, Mg²⁺, Li⁺, K⁺, Ca²⁺ and N⁺(R)₄ salts of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (-)-5-methoxy-2-[[((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.

10 Claims, No Drawings

5,714,504

1

COMPOSITIONS

This application is a continuation-in-part of application Ser. No. 08/256,174, filed as PCT/SE94/00509, May 27, 1994.

FIELD OF THE INVENTION

The present invention is directed to new compounds of high optical purity and crystalline salts thereof, their use in medicine, a process for their preparation and their use in the manufacture of pharmaceutical preparation. The invention also relates to novel intermediates in the preparation of the compounds of the invention.

BACKGROUND OF THE INVENTION

The compound 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, having the generic name omeprazole, and therapeutically acceptable alkaline salts thereof are described in U.S. Pat. No. 4,255,431 to Junggren et al., EP 5129 and EP 124 495, respectively. Omeprazole and its alkaline salts are effective gastric acid secretion inhibitors, and are useful as antiulcer agents. The compounds, being sulfoxides, have an asymmetric center in the sulfur atom, i.e. exist as two optical isomers (enantiomers).

The separation of the enantiomers of omeprazole in analytical scale is described in e.g. J. Chromatography, 532 (1990), 305-19 and in a preparative scale in DE 4035455. The latter has been done by using a diastereomeric ether which is separated and thereafter hydrolysed in an acidic solution. Under the acidic conditions needed for hydrolysis of the attached group, omeprazole is quite sensitive and the acid has to be quickly neutralized with a base to avoid degradation of the acid-sensitive compound. In the above mentioned application (DE 4035455) this is done by adding the reaction mixture containing concentrated sulfuric acid to a concentrated solution of NaOH. This is disadvantageous because there is a great risk of locally reaching pH values between 1-6, which would be devastating for the substance. Moreover, instantaneous neutralization will create heat which will be difficult to handle in large scale production.

There is no example in the known prior art of any isolated or characterized salt of optically pure omeprazole, i.e. of single enantiomers of omeprazole or of any isolated or characterized salt of any optically pure omeprazole analogue.

SUMMARY OF THE INVENTION

It is desirable to obtain compounds with improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation. The present invention provides such compounds, which are novel salts of single enantiomers of omeprazole.

A preferred embodiment of the present invention provides pure crystalline enantiomeric salts of omeprazole and methods for the preparation thereof.

A more preferred embodiment of the present invention is directed to an optically pure crystalline enantiomeric magnesium salt of omeprazole and method for the preparation thereof.

A nonaqueous process according to the present invention is directed to the preparation of crystalline forms of an optically pure enantiomer of omeprazole magnesium salt or analogues thereof which includes steps of stirring a crude

2

preparation of the omeprazole enantiomer under nitrogen into a methanolic magnesium methoxide solution, precipitating inorganic magnesium salt with addition of a small amount of water, removing any precipitated inorganic magnesium salts, concentrating the residual methanolic solution, precipitating the omeprazole enantiomer by adding acetone to the residual solution, and filtering off the optically pure enantiomer crystals of magnesium omeprazole or analogues thereof.

The present invention in a further aspect provides a novel method for preparing the novel compounds of the invention in large scale. This novel method can also be used in large scale to obtain single enantiomers of omeprazole in neutral form.

The compounds according to the invention may be used for inhibiting gastric acid secretion in mammals and man. In a more general sense, the compounds of the invention may be used for the treatment of gastric acid-related diseases and gastrointestinal inflammatory diseases in mammals and man, such as gastric ulcer, duodenal ulcer, reflux esophagitis, and gastritis. Furthermore, the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable e.g. in patients on NSAID therapy, in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding. They may also be used in patients in intensive care situations, and pre- and postoperatively to prevent acid aspiration and stress ulceration. The compound of the invention may also be used for treatment or prophylaxis of inflammatory conditions in mammals, including man, especially those involving lyosomal enzymes. Conditions that may be specifically mentioned for treatment are rheumatoid arthritis and gout. The compound of the invention may also be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections.

DETAILED DESCRIPTION OF THE INVENTION


The present invention refers to the new Na^+ , Mg^{2+} , Li^+ , K^+ , Ca^{2+} and $\text{N}^+(\text{R})_4$ salts of the single enantiomers of omeprazole, where R is an alkyl with 1-4 carbon atoms, i.e. Na^+ , Mg^{2+} , Li^+ , K^+ , Ca^{2+} and $\text{N}^+(\text{R})_4$ salts of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, where R is an alkyl with 1-4 carbon atoms.

Particularly preferred salts according to the invention are the Na^+ , Ca^{2+} and Mg^{2+} salts, i.e. (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt, (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole calcium salt and (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole calcium salt.


Most preferred salts according to the invention are the optically pure Na^+ salts of omeprazole according to compounds Ia and Ib

5,714,504


3



4



and the optically pure magnesium salts of omeprazole according to compounds IIa and IIb




With the expression "optically pure Na^+ salts of omeprazole" is meant the (+)-enantiomer of omeprazole Na^+ -salt essentially free of the (-)-enantiomer of omeprazole Na^+ -salt and the (-)-enantiomer essentially free of the (+)-enantiomer, respectively. Single enantiomers of omeprazole have hitherto only been obtained as syrups and not as crystalline products. The salts defined by the present invention are easy to obtain by means of the novel specific method according to one aspect of the invention of preparing the single enantiomers of omeprazole. In contrast to the neutral forms the salts can be obtained as crystalline products. Because it is possible to purify optically impure or partially pure salts of the enantiomers of omeprazole by crystallization, they can be obtained in very high optical purity, namely $\geq 99.8\%$ enantiomeric excess (e.e.) even from an optically contaminated preparation. Moreover, the optically pure salts are stable resisting racemization both in neutral pH and basic pH, which is surprising since the known deprotonation at the carbon atom between the pyridine ring and the chiral sulfur atom was expected to cause racemization under alkaline conditions. This high stability against racemization makes it possible to use a single enantiomeric salt of the invention in therapy.

The specific method of preparation of the single enantiomers of omeprazole is a further aspect of the invention as mentioned above and it can be used to obtain the single enantiomers of omeprazole in neutral form as well as the salts thereof.

Yet a further aspect of the invention is the compound III, which is an intermediate used in the specific method of preparation.

Preparation

The optically pure compounds of the invention, i.e. the single enantiomers, are prepared by separating the two stereoisomers of a diastereomeric mixture of the following type, 5- or 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1-[acyloxymethyl]-1H-benzimidazole, formula IV



wherein the methoxy substituent in the benzimidazole moiety is in position 5 or 6, and wherein the Acyl radical is as defined below, followed by a solvolysis of each separated diastereomer in an alkaline solution. The formed single enantiomers of omeprazole are then isolated by neutralizing aqueous solutions of the salts of the single enantiomers of omeprazole with a neutralizing agent which can be an acid or an ester such as methyl formate.

The Acyl moiety in the diastereomeric ester may be a chiral acyl group such as mandeloyl, and the asymmetric center in the chiral acyl group can have either R or S configuration.

The diastereomeric esters can be separated either by chromatography or fractional crystallization.

The solvolysis usually takes place together with a base in a protic solvent such as alcohols or water, but the acyl group may also be hydrolyzed off by a base in an aprotic solvent such as dimethylsulfoxide or dimethylformamide. The reacting base may be OH^- or R^1O^- where R^1 can be any alkyl or aryl group.

To obtain the optically pure Na^+ salts of the invention, i.e. the single enantiomers of omeprazole Na^+ salts, the resulting compound is treated with a base, such as NaOH , in an aqueous or nonaqueous medium, or with NaOR^2 wherein R^2 is an alkyl group containing 1-4 carbon atoms, or with NaNH_2 . In addition, alkaline salts wherein the cation is Li^+ or K^+ may be prepared using lithium or potassium salts of the above mentioned bases. In order to obtain the crystalline form of the Na^+ salt, addition of NaOH in a non-aqueous medium such as a mixture of 2-butanone and toluene, is preferred.

To obtain the optically pure Mg^{2+} salts of the invention, optically pure enantiomeric Na^+ salts may be treated with an aqueous solution of an inorganic magnesium salt such as MgCl_2 , whereupon the Mg^{2+} salts are precipitated. The optically pure Mg^{2+} salts may also be prepared by treating single enantiomers of omeprazole with a base, such as

5,714,504

5

$Mg(OR^3)_2$, wherein R^3 is an alkyl group containing 1-4 carbon atoms, in a non-aqueous solvent such as alcohol (only for alcoholates), e.g. ROH, or in an ether such as tetrahydrofuran. In an analogous way, also alkaline salts wherein the cation is Ca^{2+} can be prepared, using an aqueous solution of an inorganic calcium salt such as $CaCl_2$.

Alkaline salts of the single enantiomers of the invention are, as mentioned above, beside the sodium salts (compounds Ia and Ib) and the magnesium salts (compounds IIa and IIb), exemplified by their salts with Li^+ , K^+ , Ca^{2+} and $N^+(R)_4$, where R is an alkyl with 1-4 C-atoms.

For clinical use the single enantiomers, i.e. the optically pure compounds, of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other modes of administrations. The pharmaceutical formulations contain the single enantiomers of the invention normally in combination with a pharmaceutically acceptable carrier. The carrier may be in form of a solid, semi-solid or liquid diluent, or capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compound is between 0.1-95% by weight of the preparation, between 0.2-20% by weight in preparations for parenteral use and between 1-50% by weight in preparations for oral administration.

In the preparation of pharmaceutical formulations in form of dosage units for oral administration the optically pure compound may be mixed with a solid, powdered carrier, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivates, gelatin or another suitable carrier, stabilizing substances such as alkaline compounds e.g. carbonates, hydroxides and oxides of sodium, potassium, calcium, magnesium and the like as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethyleneglycol waxes. The mixture is then processed into granules or pressed into tablets. Granules and tablets may be coated with an enteric coating which protects the active compound from acid catalyzed degradation as long as the dosage form remains in the stomach. The enteric coating is chosen among pharmaceutically acceptable enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers and the like, if preferred in combination with a suitable plasticizer. To the coating various dyes may be added in order to distinguish among tablets or granules with different amounts of the active compound present.

Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Soft gelatine capsules may also be enteric-coated as described above.

Hard gelatine capsules may contain granules or enteric-coated granules of the active compound. Hard gelatine capsules may also contain the active compound in combination with a solid powdered carrier such as lactose, saccharose, sorbitol, mannitol, potato starch, amylopectin, cellulose derivates or gelatin. The capsules may be enteric-coated as described above.

Dosage units for rectal administration may be prepared in the form of suppositories which contain the active substance mixed with a neutral fat base, or they may be prepared in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules, or they may be prepared in the form of a ready-made micro enema, or they may be prepared in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

6

Liquid preparation for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing from 0.2% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and/or polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations for oral administration may also be prepared in the form of dry powder to be reconstituted with a suitable solvent prior to use.

Solutions for parenteral administrations may be prepared as solutions of the optically pure compounds of the invention in pharmaceutically acceptable solvents, preferably in a concentration from 0.1 to 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may be manufactured in different unit dose ampoules or vials. Solutions for parenteral administration may also be prepared as dry preparations to be reconstituted with a suitable solvent extemporaneously before use.

The typical daily dose of the active compound will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.

The invention is illustrated by the following examples using preferred procedures for the preparation of optically pure sodium salts and magnesium salts.

The processes described below for optically pure enantiomeric sodium salts of omeprazole result in change of directions from (-) to (+) optical rotation and, vice versa, from (+) to (-) optical rotation when preparing the sodium salt from the neutral form of omeprazole and again, when preparing the magnesium salt from the sodium salt of omeprazole.

EXAMPLE 1

Preparation of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Sodium Salt

100 mg (0.3 mmol) of (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (contaminated with 3% of the (+)-isomer) was dissolved in 1 ml of 2-butanone with stirring. 60 μ l of an aqueous solution of 5.0M sodium hydroxide and 2 ml of toluene were added. The resultant mixture was non-homogeneous. In order to obtain a clear solution, more 2-butanone was added (ca 1 ml) and the mixture was stirred at ambient temperature over night. The formed precipitate was filtered off and washed with ether. There was obtained 51 mg (46%) of the title compound as white crystals m.p. (decomposition) 246°-248° C. The optical purity (e.e.) which was analyzed by chiral column chromatography was $\geq 99.8\%$. $[\alpha]_D^{20} = +42.8^\circ$ (concentration, c=0.5%, water).

NMR data are given below.

EXAMPLE 2

Preparation of (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Sodium Salt

100 mg-(0.3 mmol) of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole (contaminated with 3% of the (-)-isomer) was dissolved in 1 ml of 2-butanone with stirring. 60 μ l of

5,714,504

7

an aqueous solution of 5.0M sodium hydroxide and 2 ml of toluene were added. The resultant mixture was non-homogeneous. In order to obtain a clear solution, more 2-butanone was added (ca 1 ml) and the mixture was stirred at ambient temperature over night. The formed precipitate was filtered off and washed with ether. There was obtained 56 mg (51%) of the title compound as white crystals m.p. (decomposition) 247°–249° C. The optical purity (e.e.) which was analyzed by chiral column chromatography was ≥99.8%. $[\alpha]_D^{20} = -44.1^\circ$ (c=0.5%, water).

NMR data are given below.

EXAMPLE 3

Preparation of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Magnesium Salt

2.9 ml of a 0.1M solution of NaOH was added to 0.10 g (0.29 mmol) (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. To this mixture 2 ml methylene chloride was added, and after mixing in a separatory funnel the aqueous solution was separated off. A solution of 14 mg (0.145 mmol) MgCl₂ in water was added dropwise. The formed precipitate was isolated by centrifugation, and 52 mg (50%) of the product was isolated as an amorphous powder. The optical purity (e.e.) was 98%, and thus the same as the starting material. The optical purity was determined by chromatography on an analytical chiral column. $[\alpha]_D^{20} = +101.2^\circ$ (c=1%, methanol). The Mg content of the sample was found to be 3.0% shown by atomic absorption spectroscopy.

EXAMPLE 4

Preparation of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Magnesium Salt

(–)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt (0.500 g, 1.36 mmol) was dissolved in water (10 ml). To this mixture 10 ml of an aqueous solution of MgCl₂·H₂O (138 mg, 0.68 mmol) was added dropwise and the formed precipitate was isolated by centrifugation. There was obtained 418 mg (86%) of the product as a white powder. The optical purity (ee) of the product was 99.8% which was the same as the optical purity of the starting material. The optical purity was determined by chromatography on an analytical chiral column. $[\alpha]_D^{20} = +129.9^\circ$ (c=1%, methanol).

EXAMPLE 5

Preparation of (–)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Magnesium Salt

(+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt (0.165 g, 0.45 mmol) was dissolved in water (3 ml). To this mixture 2 ml of an aqueous solution of MgCl₂·H₂O (46 mg, 0.23 mmol) was added dropwise and the formed precipitate was isolated by centrifugation. There was obtained 85 mg (51%) of the product as a white powder. The optical purity (ee) of the product was 99.9% which was the same or better as the optical purity of the starting material. The optical purity was determined by chromatography on an analytical chiral column. $[\alpha]_D^{20} = -128.2^\circ$ (c=1%, methanol).

8

TABLE 1

Ex.	Solvent	NMR data δ ppm
5	DMSO-d ₆	2.20 (s, 3H), 2.22 (s, 3H), 3.69 (s, 3H), 3.72 (s, 3H), 500 MHz 4.37 (d, 1H), 4.75 (d, 1H), 6.54 (dd, 1H), 6.96 (d, 1H), 7.30 (d, 1H), 8.21 (s, 1H)
10	DMSO-d ₆	2.20 (s, 3H), 2.22 (s, 3H), 3.69 (s, 3H), 3.72 (s, 3H), 500 MHz 4.38 (d, 1H), 4.73 (d, 1H), 6.54 (dd, 1H), 6.96 (d, 1H), 7.31 (d, 1H), 8.21 (s, 1H)

A preferred method for preparing optically pure omeprazole enantiomer crystal salts of magnesium is described in Examples 6 and 7.

EXAMPLE 6

Enhancement of the Optical Purity by Preparing the Magnesium Salt of (–)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in Nonaqueous Solution Followed by Crystallization of Said Salt

Magnesium (0.11 g, 4.5 mmol) was dissolved and reacted with methanol (50 ml) at 40° C. with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90% (–)-isomer and 10% (+)-isomer] of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2 mmol) was added to the magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts. After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (+)-isomer), with an optical purity (enantiomeric excess, e.e.) of 80%. This mixture was diluted with acetone (100 ml) and after stirring at room temperature for 15 minutes, a white precipitate was obtained. Additional stirring for 15 mintues and thereafter filtration afforded 1.3 g (50%) of the title compound as white crystals. Chiral analyses of the crystals and mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the crystals and mother liquor was found to be 98.4 e.e. and 64.4% e.e., respectively. Thus, the optical purity (e.e.) has been enhanced from 80% to 98.4% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The product was crystalline as shown by powder X-ray diffraction and the magnesium content was 3.44% as shown by atomic absorption spectroscopy. $[\alpha]_D^{20} = -131.5^\circ$ (c=0.5%, methanol).

EXAMPLE 7

Enhancement of the Optical Purity by Preparing the Magnesium Salt of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in Nonaqueous Solution Followed by Crystallization of Said Salt

Magnesium (0.11 g, 4.5 mmol) was dissolved and reacted with methanol (50 ml) at 40° C. with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90% (+)-isomer and 10% (–)-isomer] of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2

5,714,504

9

mmol) was added to the magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts. After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (-)-isomer), with an optical purity (e.e.) of 80%. This mixture was diluted with acetone (100 ml) and after stirring at room temperature for one hour, a white precipitate was obtained. Additional stirring for 30 minutes and thereafter filtration afforded 0.35 g of the title compound as white crystals. Additional stirring of the mother liquor for 24 hours at room temperature afforded another 1.0 g (total yield=52%). Chiral analyses of the crystals and the second mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the two crystal fractions was 98.8% e.e. and 99.5% e.e., respectively. The optical purity of the mother liquor was found to be 57% e.e. Thus, the optical purity (e.e.) has been enhanced from 80% to approximately 99% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The first precipitation was crystalline as shown by powder X-ray diffraction and the magnesium content of the same fraction was 3.49% as shown by atomic absorption spectroscopy. $[\alpha]_D^{20}=+135.6^\circ$ ($c=0.5\%$, methanol).

The crystalline salt according to Example 6 is most preferred.

Preparation of the synthetic intermediates according to the invention is described in the following examples.

EXAMPLE 8

Preparation of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(R*)-mandeloyloxyethyl]-1*H*-benzimidazole

A solution of 3.4 g sodium hydroxide in 40 ml water was added to a mixture of 14.4 g (42 mmol) tetrabutylammonium hydrogen sulfate and 6.4 g (42 mmol) (R)-(-)-mandelic acid. The mixture was extracted with 400 ml chloroform. After separation, the organic extract was heated to reflux with 16.6 g (42 mmol) of the racemate of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[chloromethyl]-1*H*-benzimidazole. Evaporation of the solvent was followed by dilution with 100 ml dichloromethane and 700 ml ethyl acetate. The mixture was washed with 3×200 ml water and the organic solution was dried over $MgSO_4$ and then evaporated. The crude material was purified by recrystallization from 100 ml acetonitrile, giving 8.1 g of the title compound (38%) as a diastereomeric mixture.

NMR data are given below.

EXAMPLE 9

Separation of the More Hydrophilic Diastereomer of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(R*)-mandeloyloxyethyl]-1*H*-benzimidazole

The diastereomers of the title compound in Example 8 were separated using reversed phase chromatography (HPLC). Approximately 300 mg of the diastereomeric mixture was dissolved in 10 ml hot acetonitrile which was diluted with 10 ml of a mixture of aqueous 0.1M ammoniumacetate and acetonitrile (70/30). The solution was injected to the column and the compounds were eluted with a mixture of aqueous 0.1M ammoniumacetate and acetonitrile (70/30).

10

The more hydrophilic isomer was easier to obtain pure than the less hydrophilic one. The work up procedure for the fraction which contained pure isomer was as follows; extraction with dichloromethane, washing the organic solution with aqueous 5% sodium hydrogen carbonate solution, drying over Na_2SO_4 and evaporation of the solvent on a rotavapor (at the end of the evaporation the removal of acetonitrile was facilitated by adding more dichloromethane). Using 1.2 g of the diastereomeric mixture with the above mentioned technique, the more hydrophilic isomer, 410 mg, was obtained in a pure state as a colorless syrup.

NMR data are given below.

EXAMPLE 10

Preparation of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(S*)-mandeloyloxyethyl]-1*H*-benzimidazole

The product was obtained from 8.1 g (202 mmol) sodium hydroxide in 100 ml water, 34.4 g (101 mmol) tetrabutylammonium hydrogen sulfate, 15.4 g (101 mmol) (S)-(+) mandelic acid and 39.9 g (101 mmol) of the racemate of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[chloromethyl]-1*H*-benzimidazole using the same procedure as in Example 8. Recrystallization from 100 ml acetonitrile yielded 21.3 g, i.e. 41% of the title compound as a diastereomeric mixture.

NMR data are given below.

EXAMPLE 11

Separation of the More Hydrophilic Diastereomer of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(S*)-mandeloyloxyethyl]-1*H*-benzimidazole

The diastereomers of the title compound in Example 10 were separated using reversed phase chromatography (HPLC) in the same way as in Example 7, but using the diastereomeric mixture of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(S*)-mandeloyloxyethyl]-1*H*-benzimidazole instead of the (R)-mandelic ester used in Example 9. Using 2.1 g of the diastereomeric mixture, the more hydrophilic isomer, 760 mg, was obtained in a pure state as a colorless syrup.

NMR data are given below.

EXAMPLE 12

Preparation of (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1*H*-benzimidazole

0.23 g (0.45 mmol) of the more hydrophilic diastereomer of 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[*(R*)-mandeloyloxyethyl]-1*H*-benzimidazole was dissolved in 15 ml methanol. A solution of 36 mg (0.9 mmol) sodium hydroxide in 0.45 ml water was added, and after 10 minutes the mixture was evaporated on a rotavapor. The residue was partitioned between 15 ml water and 15 ml dichloromethane. The organic solution was extracted with 15 ml water and to the combined aqueous solutions was added 85 μ l (1.4 mmol) methyl formate. After 15 minutes the mixture was extracted with 3×10 ml dichloromethane. The organic solution was dried over Na_2SO_4 and then evaporated. There was obtained 0.12 g (77%) of the title compound as a colorless syrup. The optical purity (e.e.)

5,714,504

11

which was analyzed by chiral column chromatography was 94%. $[\alpha]_D^{20} = -155^\circ$ ($c=0.5\%$ chloroform).

NMR data are given below

EXAMPLE 13

Preparation of (+)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole

0.76 g (1.5 mmol) of the more hydrophilic diastereomer of 6-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-[(S)-mandeloyloxymethyl]-1H-benzimidazole was dissolved in 50 ml methanol. A solution of 0.12 mg (3.0 mmol) sodium hydroxide in 1.5 ml water was added, and after 10 minutes the mixture was evaporated on a rotavapor. The residue was partitioned between 25 ml water and 25 ml dichloromethane. The organic solution was extracted with 25 ml water and to the combined aqueous solutions was added 200 μ l (3.2 mmol) methyl formate. After 15 minutes the mixture was extracted with 3 \times 25 ml dichloromethane. The organic solution was dried over Na_2SO_4 and then evaporated. There was obtained 0.42 g (81%) of the title compound as a colorless syrup. The optical purity (e.e.) which was analyzed by chiral column chromatography was 98%. $[\alpha]_D^{20} = +157^\circ$ ($c=0.5\%$, chloroform).

NMR data are given below

TABLE 2

Ex.	Solvent	NMR data δ ppm
8.	CDCl_3 500 MHz	2.18 (s, 3H), 2.20 (s, 3H), 2.36 (s, 3H), 2.39 (s, 3H), 3.77 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 3.87 (s, 3H), 4.80 (d, 1H), 4.88 (d, 1H), 5.0 (m, 2H), 5.34 (s, 2H), 6.43 (d, 1H), 6.54 (d, 1H), 6.6–6.7 (m, 2H), 6.90 (d, 1H), 6.95–6.98 (m, 2H), 7.01 (d, 1H), 7.2–7.3 (m, 6H), 7.37 (m, 2H), 7.44 (m, 2H), 7.58 (d, 1H), 7.62 (d, 1H), 7.95 (s, 1H), 7.97 (s, 1H).
9.	CDCl_3 500 MHz	2.20 (s, 3H), 2.36 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 4.80 (d, 1H), 5.00 (d, 1H), 5.35 (d, 1H), 6.43 (d, 1H), 6.63 (d, 1H), 6.90 (d, 1H), 6.97 (dd, 1H), 7.2–7.3 (m, 3H), 7.37 (m, 2H), 7.62 (d, 1H), 7.97 (s, 1H).
10.	CDCl_3 500 MHz	2.19 (s, 3H), 2.20 (s, 3H), 2.36 (s, 3H), 2.39 (s, 3H), 3.77 (s, 3H), 3.78 (s, 3H), 3.83 (s, 3H), 3.87 (s, 3H), 4.80 (d, 1H), 4.88 (d, 1H), 5.0 (m, 2H), 5.34 (s, 2H), 6.43 (d, 1H), 6.54 (d, 1H), 6.6–6.7 (m, 2H), 6.90 (d, 1H), 6.95–6.98 (m, 2H), 7.01 (d, 1H), 7.2–7.3 (m, 6H), 7.37 (m, 2H), 7.44 (m, 2H), 7.58 (d, 1H), 7.62 (d, 1H), 7.95 (s, 1H), 7.97 (s, 1H).
11.	CDCl_3 500 MHz	2.20 (s, 3H), 2.36 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 4.80 (d, 1H), 5.00 (d, 1H), 5.35 (d, 1H), 6.43 (d, 1H), 6.63 (d, 1H), 6.90 (d, 1H), 6.97 (dd, 1H), 7.2–7.3 (m, 3H), 7.37 (m, 2H), 7.62 (d, 1H), 7.97 (s, 1H).
12.	CDCl_3 300 MHz	2.18, (s, 3H), 2.22 (s, 3H), 3.68 (s, 3H), 3.83 (s, 3H), 4.77 (m, 2H), 6.93 (dd, 1H), \sim 7.0 (b, 1H), \sim 7.5 (b, 1H), 8.19 (s, 1H).
13.	CDCl_3	2.21 (s, 3H), 2.23 (s, 3H), 3.69 (s, 3H), 3.84 (s, 3H), 4.76 (m, 2H), 6.94 (dd, 1H), \sim 7.0 (b, 1H), \sim 7.5 (b, 1H), 8.20 (s, 1H).

Pharmaceutical preparations containing the compounds of the invention as active ingredient are illustrated in the following formulations.

Syrup

A syrup containing 1% (weight per volume) of active substance was prepared from the following ingredients:

Compound according to Example 1	1.0 g
Sugar, powder	30.0 g
Saccharine	0.6 g

12

-continued

5	Glycerol	5.0 g
	Flavoring agent	0.05 g
	Ethanol 96%	5.0 g
	Distilled water q.s. to a final volume of	100 ml

Sugar and saccharine were dissolved in 60 g of warm water. After cooling the active compound was added to the sugar, solution and glycerol and a solution of flavoring agents dissolved in ethanol were added. The mixture was diluted with water to a final volume of 100 ml.

Enteric-coated Tablets

An enteric coated tablet containing 50 mg of active compound was prepared from the following ingredients:

15	<u>I</u>	
20	Compound according to Example 6 as Mg salt	500 g
	Lactose	700 g
	Methyl cellulose	6 g
	Polyvinylpyrrolidone cross-linked	50 g
	Magnesium stearate	15 g
	Sodium carbonate	6 g
	Distilled water	q.s.
25	<u>II</u>	
30	Cellulose acetate phthalate	200 g
	Cetyl alcohol	15 g
	Isopropanol	2000 g
	Methylene chloride	2000 g

30 I Compound according to Example 6, powder, was mixed with lactose and granulated with a water solution of methyl cellulose and sodium carbonate. The wet mass was forced through a sieve and the granulate dried in an oven. After drying the granulate was mixed with polyvinylpyrrolidone and magnesium stearate. The dry mixture was pressed into tablet cores (10 000 tablets), each tablet containing 50 mg of active substance, in a tabletting machine using 7 mm diameter punches.

35 II A solution of cellulose acetate phthalate and cetyl alcohol in isopropanol/methylene chloride was sprayed onto the tablets I in an Accela Cota® Manesty coating equipment. A final tablet weight of 110 mg was obtained.

Solution for Intravenous Administration

40 A parenteral formulation for intravenous use, containing 4 mg of active compound per ml, was prepared from the following ingredients:

45	Compound according to Example 2	4 g
	Sterile water to a final volume of	1000 ml

50 The active compound was dissolved in water to a final volume of 1000 ml. The solution was filtered through a 0.22 μ m filter and immediately dispensed into 10 ml sterile ampoules. The ampoules were sealed.

Capsules

55 Capsules containing 30 mg of active compound were prepared from the following ingredients:

60	Compound according to Example 6	300 g
	Lactose	700 g
	Microcrystalline cellulose	40 g
	Hydroxypropyl cellulose low-substituted	62 g
	Disodium hydrogen phosphate	2 g
	Purified water	q.s.

65 The active compound was mixed with the dry ingredients and granulated with a solution of disodium hydrogen phos-

5,714,504

13

phate. The wet mass was forced through an extruder and spheronized and dried in a fluidized bed dryer.

500 g of the pellets above were first coated with a solution of hydroxypropyl methylcellulose, 30 g, in water, 750 g, using a fluidized bed coater. After drying, the pellets were coated with a second coating as given below:

Coating solution:	
Hydroxypropyl methylcellulose phthalate	70 g
Cetyl alcohol	4 g
Acetone	200 g
Ethanol	600 g

The final coated pellets were filled into capsules.
Suppositories

Suppositories were prepared from the following ingredients using a welding procedure. Each suppository contained 40 mg of active compound.

Compound according to Example 1	4 g
Witepsol H-15	180 g

The active compound was homogenously mixed with Witepsol H-15 at a temperature of 41° C. The molten mass was volume filled into pre-fabricated suppository packages to a net weight of 1.84 g. After cooling the packages were heat sealed. Each suppository contained 40 mg of active compound.

Stability Towards Racemization at Different pH Values

The stability of the optically pure compounds of the invention against racemization has been measured at low concentrations in a refrigerator in aqueous buffer solutions at pH 8, 9.3, 10 and 11.2. The stereochemical stability was measured by comparing the optical purity for the (-)-isomer of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in buffer solution immediately after dissolving and after several days. The measurement was performed by chromatography on an analytical chiral column. The surprising high stereochemical stability in alkaline conditions for the compounds of invention is exemplified by the fact that no racemization for the test compound was obtained at pH 11.2 even after 21 days. At pH 8, 9.3 and 10, the chemical degradation of the compound is more apparent which makes the racemization measurement more difficult to perform, however at none of these pH values a detectable racemization was obtained after 16 days.

In another racemization experiment with the optically pure compounds of the invention, an aqueous phosphate buffer solution (pH=11) of the (+)-isomer of 5-methoxy-2-

14

[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt ($c=10^{-5}$ M) was warmed for 26 hours at 37° C. without any racemization at all being observed.

5. What is claimed is:

1. A pharmaceutical formulation for oral administration comprising a pure solid state alkaline salt of the (-)-enantiomer of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and a pharmaceutically acceptable carrier.

2. The pharmaceutical formulation according to claim 1 wherein the solid state salt is optically pure.

3. The pharmaceutical formulation according to claim 1, wherein the alkaline salt is a Na^+ , Mg^{2+} , Li^+ , K^+ , Ca^{2+} or $\text{N}^+(\text{R})_4$ salt.

4. The pharmaceutical formulation according to claim 1, wherein the solid state salt is in substantially crystalline form.

5. The pharmaceutical formulation according to claim 1 wherein the alkaline salt is a sodium or magnesium salt.

6. A method of inhibiting gastric acid secretion comprising the oral administration of a pharmaceutical formulation comprising a therapeutically effective amount of a pure solid state alkaline salt of the (-)-enantiomer of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and a pharmaceutically acceptable carrier.

7. A method for the treatment of gastrointestinal inflammatory disease comprising the oral administration to a mammal including man in need of such treatment of a

30 pharmaceutical formulation comprising a therapeutically effective amount of a pure solid state alkaline salt of the (-)-enantiomer of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and a pharmaceutically acceptable carrier.

35 8. A method for the treatment of gastrointestinal inflammatory diseases comprising the oral administration to a mammal including man in need of such treatment a composition comprising an effective amount of the pure (-)-enantiomer of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and a pharmaceutically acceptable carrier.

40 9. A method of inhibiting gastric acid secretion comprising the oral administration of a pharmaceutical composition comprising an effective amount of the pure (-)-enantiomer of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and a pharmaceutically acceptable carrier.

45 10. The method of claim 6 or 7 wherein the alkaline salt is a Na^+ , Mg^{2+} , Li^+ , K^+ , Ca^{2+} or $\text{N}^+(\text{R})_4$ salt.

* * * * *

EXHIBIT B



US006875872B1

(12) **United States Patent**
Lindberg et al.

(10) **Patent No.:** US 6,875,872 B1
(45) **Date of Patent:** Apr. 5, 2005

(54) **COMPOUNDS**

- (75) Inventors: **Per Lennart Lindberg**, Mölndal (SE);
Sverker Von Unge, Fjärås (SE)
- (73) Assignee: **AstraZeneca**, Sodertälje (SE)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/690,044**(22) Filed: **Oct. 16, 2000****Related U.S. Application Data**

- (63) Continuation of application No. 09/187,277, filed on Nov. 6, 1998, which is a continuation of application No. 08/899,931, filed on Jul. 24, 1997, now abandoned, which is a continuation of application No. 08/376,512, filed on Jan. 23, 1995, now Pat. No. 5,714,504, which is a continuation-in-part of application No. 08/256,174, filed on Jun. 28, 1994, now Pat. No. 5,693,818.

(30) **Foreign Application Priority Data**

May 28, 1993 (SE) 9301830

- (51) Int. Cl.⁷ **C07D 401/12**
- (52) U.S. Cl. **546/273.7; 514/338**
- (58) Field of Search 514/338; 546/273.7

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,636,499 A	1/1987	Brandstrom et al.	514/222
4,738,974 A	4/1988	Brändström	514/338
4,786,505 A	11/1988	Lovgren et al.	424/468
4,853,230 A	8/1989	Lovgren et al.	424/466
5,045,321 A	9/1991	Makino et al.	424/475
5,690,960 A	11/1997	Bengtsson et al.	424/480
5,714,504 A	2/1998	Lindberg et al.	514/338
5,817,338 A	10/1998	Bergstrand et al.	424/468
5,877,192 A	3/1999	Lindberg et al.	514/338
5,888,535 A	3/1999	Gray	424/449
5,900,424 A	5/1999	Källström et al.	514/338
6,214,464 B1 *	4/2001	Huston et al.	546/273.7

FOREIGN PATENT DOCUMENTS

DE	4035455	11/1990
DE	4035455	5/1992
DE	40 35 455 A1	5/1997
EP	0005129	4/1981
EP	0 124 495 A2	11/1984
EP	01 662 87 B1	1/1986
EP	0124495	1/1987
EP	6247983	4/1987
EP	0365947	5/1990
EP	0 652 872	5/1995
EP	0 005 129 A1	10/1999
WO	WO 88/03921	6/1988
WO	9222284	12/1992
WO	9427988	12/1994
WO	9501783	1/1995
WO	9501977	1/1995
WO	9601623	1/1996
WO	9602535	2/1996

OTHER PUBLICATIONS

- Brandstrom "Omeprazole salts" CA 102:137795 (1985).*
- Erlandsson et al "Resolution of the enantiomers of omeprazole . . ." CA 114:74595 (1991).*
- Kohl et al. "Enantiomerically pure . . ." CA 117:90285 (1992).*
- Brandstrom "omeprazole salts" CA 102:137795 (1985).*
- Kaelstroem et al. "Preparation of magnesium omeprazole in a crystalline form", CA122:196964 (1995).*
- Lindberg et al. "Preparation of optically pure omeprazole salts" CA 128:154082 (1998).*
- Seminars on Organic synthesis vol. 18, 1958 by Japanese Chemical Society.*
- Deutsche Apothekerzeitung No. 24 pp. 84-85, 1976.*
- Written Decision of the Opposition Panel of the European Patent Office, in the matter of EP 0 652 872, dated Feb. 26, 2004.
- Tillet, J.G., et al., "Nucleophilic Substitution as Tricoordinate Sulfur", Chemical Reviews, 1976, vol. 76, No. 6.
- J. March, Advanced Organic Chemistry, 4th edition (1992), John Wiley & Sons, pp. 100, 120, 121, 378 and 379.
- A. Pilbrant and C. Cederberg, "Development of an oral formulation of omeprazole", Scandinavian Journal of Gastroenterology, vol. 20, Supplement 108 (1985) , pp. 113-120.
- Beyer Walter, Lehrbuch der Organischen Chemie [Textbook of organic chemistry], 22nd edition (1991), S. Hirzel Verlag, Stuttgart, pp. 735-736.
- H.J. Federsel, "Chiral Arzneimittel", Chemie in unserer Zeit (1993)No. 2, VCH Vertragsgesellschaft mbH, pp. 78-87.
- D. Enders and R.W. Hoffmann, "Asymmetrische Synthese", Chemie in unserer Zeit (1985)No. 6, VCH Vertragsgesellschaft mbH, pp. 177-190.
- Clinical studies A and B by Astra Hässle AB, introduced into the grant proceedings.
- Methoden der Organischen Chemie (Houben Weyl) [Methods of organic chemistry, Houben Weyl], vol. I/1, 1958, chapter "Crystallization", pp. 345-389.
- P. Lindberg et al., "Omeprazole: The First Proton Pump Inhibitor", Medicinal Research Reviews, vol. 10, No. 1, 1-54 (1990).

(Continued)

Primary Examiner—Celia Chang(74) *Attorney, Agent, or Firm—White & Case LLP*(57) **ABSTRACT**

The novel optically pure compounds Na^+ , Mg^{2+} , Li^+ , K^+ , Ca^{2+} and $\text{N}^+(\text{R})_4$ salts of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.

12 Claims, No Drawings

US 6,875,872 B1

Page 2

OTHER PUBLICATIONS

- P. Erlandsson et al., "Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase: The effect of the enantiomers of omeprazole on gastric glands", *Journal of Chromatography* 532 (1990) 305–319.
- W. Forth et al., "*Allgemeine und spezielle Pharmakologie und Toxikologie*". [*General and special pharmacology and toxicology*], Wissenschaftsverlag, 6th edition 1992, pp. 33, 34, 55–57, 70, 472 and 473.
- M. Eichelbaum et al., Effects of Verapamil on P-R-Intervals in Relation to Verapamil Plasma Levels Following Single i.v. and Oral Administration and During Chronic Treatment, *Klinische Wochenschrift* 58, 919–925 (1980).
- P. Dayer et al., Interindividual Variation of Beta-Adrenoceptor Blocking Drugs, Plasma Concentration and Effect: Influence of Genetic Status on Behavior of Atenolol, Bopindolol and Metoprolol, *Eur. J. Clin. Pharmacol.* (1985) 28(2): 149–153.
- "The result of a recent study comparing all PPI's currently on the market".
- P. Fresenius, "Organic Chemical Nomenclature, Introduction to the Basic Principles", Ellis Horwood Limited, p. 127.
- S. Yamada and S. Narita, "Synthesis and Isomerization of Optical Active 2[6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl]sulfinyl]-1H-benzimidazole Analogs" *Chem. Pharm. Bull* 42(8), 1679–1681 (1994).
- Jacobus et al., "Racemization and Cleavage of Sulfoxides by Methylolithium", *Journal of the American Chemical Society* 89:20; pp. 5228–5234 (1967).
- Tanaka, M. et al., "Direct Determination of Pantoprazole Enantiomers in Human Serum by Reversed-Phase High-Performance Liquid Chromatography Using a Cellulose-Based Chiral Stationary Phase and Column-Switching System as a Sample Cleanup Procedure", *Analytical Chemistry*, vol. 68, No. 9, 1513–1516 (1996).
- Cass et al., "Enantiomeric determination of pantoprazole in human plasma by multidimensional high-performance liquid chromatography", *J. Chromatography B*, 766 (2001) 153–160.
- Comprehensive Medical Chemistry, Pergamon Press (1990), vol. 2, pp. 193–205.
- Renberg et al., "Identification of Two Main Urinary Metabolites of [¹⁴C]Omeprazole in Humans", *Drug Metabolism and Disposition*, vol. 17, (1989) 69–76.
- Abstract #35, Synthesis and Biological Activity of Enantiomers of H⁺K⁺-ATPase Inhibiting 2-(2-Pyridyl-methyl)sulphinyl-benzimidazoles (PSBs) from Program of the Fourth International Symposium of Chiral Discrimination, Sep. 19–22, 1993, Montreal, Quebec, Canada.
- In the matter of EP 0 652 872, Notice of Opposition and Opposition Brief in the name of Ratiopharm GmbH, dated Jul. 18, 2001.
- In the matter of EP 0 652 872, Response to the Opposition Brief by AstraZeneca AB, dated Mar. 27, 2002.
- In the matter of EP 0 652 872, third party observations, dated May 30, 2002.
- In the matter of EP 0 652 872, opponent submission, dated Jan. 22, 2003.
- In the matter of EP 0 652 872, summons to oral proceedings, dated Jul. 15, 2003.
- In the matter of EP 0 652 872, opponent submission, dated Oct. 21/23, 2003.
- In the matter of EP 0 652 872, patentee submission, dated Oct. 24, 2003.
- EPO Notice upholding claims 1–15 of EP 0 652 872, dated Nov. 25, 2003.
- In the matter of EP 0 652 872, written decision from EPO, "when available".
- CA 117:90292, Palomo et al. (1992).
- Erlandson et al. "Resolution of the enantiomers of omeprazole . . ." *J. Chromatography* (1990) 532:305–319.
- Chang et al. 1995 "Interphenotype differences . . ." *Brit. J. Clinical Pharmacology* 39:511–518.
- Rost et al. (1994) "Accelerated caffeine metabolism after omeprazole . . ." 55:402–411.
- Rost et al. (1992) "Increase of cytochrome P4501A2 activity . . ." 52; 170–180.
- Marle et al. "Determination of binding affinity of enantiomers . . ." *J>Chromatography* (1988) 456:323–33.
- Cairns, et al. "Enantioselective HPLC determination . . ." *Journal of Chromatography* 8,666 (1995) 323–328.
- Yamada et al. "Synthesis and isomerization of optical active . . ." *Chem. Pharm. Bull.* 42 (8) (1994) 1679–1681.
- K. Miwa et al. *Jpn. Pharmacol. Ther.* "Proton pump inhibitor in rats, mice and dogs" 18 (1990) 165–187 (transl.).
- H. Katsuki et al. Determination of R(+)–and S(–)-Lansoprazole *Pharmaceutical Research* 13(4) (1996) 611–615.
- M. Tanaka et al. "Direct determination of pantoprazole enantiomers . . ." *Anal. Chem.* 68 (1996) 1513–1516.
- P. Lindberg et al. "Omeprazole: The first proton pump inhibitor" *Medicinal Res. Rev.* 10 (1990) 2–50.
- P. Lindberg et al. The mechanism of action of . . . omeprazole *Journal of Medicinal Chemistry* 29 (1986) 1327.
- A. Branstrom "Chemical reactions . . ." Reprint from *ACTA Chemica Scandinavica* 43 (1989) 536–611.
- K. Sigrist-Nelson et al. "Ro 18-5364, a potent inhibitor of the gastric (H³⁰ +K⁺) -ATPase" *Eur. J. Bioch.* 166 (1987) 453.
- Sverker von Unge et al., Stereochemical assignment of the enantiomers of omeprazole from X-ray analysis of a fenchylloxymethyl derivative of (+)-(R)-omeprazole.
- Japanese Chemical Society: Special Topics in Experimental Chemistry—Organic Reactions II (1958).
- Communication, dated Mar. 1, 2004, pursuant to Article 115(2) EPC.
- Translation of Grounds of Appeal by Appellant ratiopharm GmbH.
- PubMed Abstract by K.M. Williams, *Clin. Exp Pharmacol Physiol.* 1989, 16(6): 465–70.
- PubMed Abstract by E.J. Ariens, *Eur J Clin Pharmacol.* 1991, 41(2): 89–93.
- PubMed Abstract by R.H. Levy et al., *Pharm Res.* 1991, 8(5): 551–6.
- PubMed Abstract by I.W. Wainer, *Am. J Hosp Pharm.* 1992 49:S4–8.
- PubMed Abstract by W.R. Crom, *Am J Hosp Pharm.* 1992, 49: S9–14.
- PubMed Abstract by F. Jamali, *J Clin Pharmacol.* 1992, 32(10):930–4.

* cited by examiner

US 6,875,872 B1

1
COMPOUNDS

This is a continuation of pending U.S. patent application Ser. No. 09/187,277, filed Nov. 6, 1998, which is a continuation of U.S. patent application Ser. No. 08/899,931, filed Jul. 24, 1997, abandoned, which is a continuation application of U.S. patent application Ser. No. 08/376,512, filed Jan. 23, 1995, now U.S. Pat. No. 5,714,504, which is a continuation-in-part application of U.S. patent application Ser. No. 08/256,174, filed Jun. 28, 1994, now U.S. Pat. No. 5,693,818.

FIELD OF THE INVENTION

The present invention is directed to new compounds of high optical purity and crystalline salts thereof, their use in medicine, a process for their preparation and their use in the manufacture of pharmaceutical preparation. The invention also relates to novel intermediates in the preparation of the compounds of the invention.

BACKGROUND OF THE INVENTION

The compound 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, having the generic name omeprazole, and therapeutically acceptable alkaline salts thereof are described in U.S. Pat. No. 4,255,431 to Junggren et al., EP 5129 and EP 124 495, respectively. Omeprazole and its alkaline salts are effective gastric acid secretion inhibitors, and are useful as antiulcer agents. The compounds, being sulfoxides, have an asymmetric center in the sulfur atom, i.e. exist as two optical isomers (enantiomers).

The separation of the enantiomers of omeprazole in analytical scale is described in e.g. J. Chromatography, 532 (1990), 305-19 and in a preparative scale in DE 4035455. The latter has been done by using a diastereomeric ether which is separated and thereafter hydrolysed in an acidic solution. Under the acidic conditions needed for hydrolysis of the attached group, omeprazole is quite sensitive and the acid has to be quickly neutralized with a base to avoid degradation of the acid-sensitive compound. In the above mentioned application (DE 4035455) this is done by adding the reaction mixture containing concentrated sulfuric acid to a concentrated solution of NaOH. This is disadvantageous because here is a great risk of locally reaching pH values between 1-6, which would be devastating for the substance. Moreover, instantaneous neutralization will create heat which will be difficult to handle in large scale production.

There is no example in the known prior art of any isolated or characterized salt of optically pure omeprazole, i.e. of single enantiomers of omeprazole or of any isolated or characterized salt of any optically pure omeprazole analogue.

SUMMARY OF THE INVENTION

It is desirable to obtain compounds with improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation. The present invention provides such compounds, which are novel salts of single enantiomers of omeprazole.

A preferred embodiment of the present invention provides pure crystalline enantiomeric salts of omeprazole and methods for the preparation thereof.

A more preferred embodiment of the present invention is directed to an optically pure crystalline enantiomeric magnesium salt of omeprazole and method for the preparation thereof.

2

A nonaqueous process according to the present invention is directed to the preparation of crystalline forms of an optically pure enantiomer of omeprazole magnesium salt or analogues thereof which includes steps of stirring a crude preparation of the omeprazole enantiomer under nitrogen into a methanolic magnesium methoxide solution, precipitating inorganic magnesium salt with addition of a small amount of water, removing any precipitated inorganic magnesium salts, concentrating the residual methanolic solution, precipitating the omeprazole enantiomer by adding acetone to the residual solution, and filtering off the optically pure enantiomer crystals of magnesium omeprazole or analogues thereof.

The present invention in a further aspect provides a novel method for preparing the novel compounds of the invention in large scale. This novel method can also be used in large scale to obtain single enantiomers of omeprazole in neutral form.

The compounds according to the invention may be used for inhibiting gastric acid secretion in mammals and man. In a more general sense, the compounds of the invention may be used for the treatment of gastric acid-related diseases and an gastrointestinal inflammatory diseases in mammals and man, such as gastric ulcer, duodenal ulcer, reflux esophagitis, and gastritis. Furthermore, the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable e.g. in patients on NSAID therapy, in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding. They may also be used in patients in intensive care situations, and pre- and postoperatively to prevent acid aspiration and stress ulceration. The compound of the invention may also be used for treatment or prophylaxis of inflammatory conditions in mammals, including man, especially those involving lysozymal enzymes. Conditions that may be specifically mentioned for treatment are rheumatoid arthritis and gout. The compound of the invention may also be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections.

DETAILED DESCRIPTION OF THE INVENTION


The present invention refers to the new Na^+ , Mg^{2+} , Li^+ , K^+ , Ca^{2+} and $\text{N}^+(\text{R})_4$ salts of the single enantiomers of omeprazole, where R is an alkyl with 1-4 carbon atoms, i.e. Na^+ , Mg^{2+} , Li^+ , K^+ , Ca^{2+} and $\text{N}^+(\text{R})_4$ salts of (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, where R is an alkyl with 1-4 carbon atoms.

Particularly preferred salts according to the invention are the Na^+ , Ca^{2+} and Mg^{2+} salts, i.e. (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt, (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt, (+)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole calcium salt and (-)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole calcium salt.


Most preferred salts according to the invention are the optically pure Na^+ salts of omeprazole according to compounds Ia and Ib

US 6,875,872 B1


3



4



and the optically pure magnesium salts of omeprazole according to compounds IIa and IIb




With the expression "optically pure Na⁺ salts of omeprazole" is meant the (+)-enantiomer of omeprazole Na-salt essentially free of the (-)-enantiomer of omeprazole Na-salt and the (-)-enantiomer essentially free of the (+)-enantiomer, respectively. Single enantiomers of omeprazole have hitherto only been obtained as syrups and not as crystalline products. The salts defined by the present invention are easy to obtain by means of the novel specific method according to one aspect of the invention of preparing the single enantiomers of omeprazole. In contrast to the neutral forms the salts can be obtained as crystalline products. Because it is possible to purify optically impure or partially pure salts of the enantiomers of omeprazole by crystallization, they can be obtained in very high optical purity, namely $\geq 99.8\%$ enantiomeric excess (e.e.) even from an optically contaminated preparation. Moreover, the optically pure salts are stable resisting racemization both in neutral pH and basic pH, which is surprising since the known deprotonation at the carbon atom between the pyridine ring and the chiral sulfur atom was expected to cause racemization under alkaline conditions. This high stability against racemization makes it possible to use a single enantiomeric salt of the invention in therapy.

The specific method of preparation of the single enantiomers of omeprazole is a further aspect of the invention as mentioned above and it can be used to obtain the single enantiomers of omeprazole in neutral form as well as the salts thereof.

Yet a further aspect of the invention is the compound m, which is an intermediate used in the specific method of preparation.

Preparation

The optically pure compounds of the invention, i.e. the single enantiomers, are prepared by separating the two stereoisomers of a diastereomeric mixture of the following type, 5- or 6-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-[acyloxymethyl]-1H-benzimidazole, formula IV



wherein the methoxy substituent in the benzimidazole moiety is in position 5 or 6, and wherein the Acyl radical is as defined below, followed by a solvolysis of each separated diastereomer in an alkaline solution. The formed single enantiomers of omeprazole are then isolated by neutralizing aqueous solutions of the salts of the single enantiomers of omeprazole with a neutralizing agent which can be an acid or an ester such as methyl formate.

The Acyl moiety in the diastereomeric ester may be a chiral acyl group such as mandeloyl, and the asymmetric center in the chiral acyl group can have either R or S configuration.

The diastereomeric esters can be separated either by chromatography or fractional crystallization.

The solvolysis usually takes place together with a base in a protic solvent such as alcohols or water, but the acyl group may also be hydrolyzed off by a base in an aprotic solvent such as dimethylsulfoxide or dimethylformamide. The reacting base may be OH⁻ or R¹O⁻ where R¹ can be any alkyl or aryl group.

To obtain the optically pure Na⁺ salts of the invention, i.e. the single enantiomers of omeprazole Na⁺ salts, the resulting compound is treated with a base, such as NaOH, in an aqueous or nonaqueous medium, or with NaOR² wherein R² is an alkyl group containing 1-4 carbon atoms, or with NaNH₂. In addition, alkaline salts wherein the cation is Li⁺ or K⁺ may be prepared using lithium or potassium salts of the above mentioned bases. In order to obtain the crystalline form of the Na⁺ salt, addition of NaOH in a non-aqueous medium such as a mixture of 2-butanone and toluene, is preferred.

To obtain the optically pure Mg²⁺ salts of the invention, optically pure enantiomeric Na⁺ salts may be treated with an

US 6,875,872 B1

5

aqueous solution of an inorganic magnesium salt such as MgCl₂, whereupon the Mg²⁺ salts are precipitated. The optically pure Mg²⁺ salts may also be prepared by treating single enantiomers of omeprazole with a base, such as Mg(OR³)₂, wherein R³ is an alkyl group containing 1–4 carbon atoms, in a non-aqueous solvent such as alcohol (only for alcoholates), e.g. ROH, or in an ether such as tetrahydrofuran. In an analogous way, also alkaline salts wherein the cation is Ca²⁺ can be prepared, using an aqueous solution of an inorganic calcium salt such as CaCl₂.

Alkaline salts of the single enantiomers of the invention are, as mentioned above, beside the sodium salts (compounds Ia and Ib) and the magnesium salts (compounds IIa and IIb), exemplified by their salts with Li⁺, K⁺, Ca²⁺ and N+(R)₄, where R is an alkyl with 1–4 C-atoms.

For clinical use the single enantiomers, i.e. the optically pure compounds, of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other modes of administrations. The pharmaceutical formulations contain the single enantiomers of the invention normally in combination with a pharmaceutically acceptable carrier. The carrier may be in form of a solid, semi-solid or liquid diluent, or capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compound is between 0.1–95% by weight of the preparation, between 0.2–20% by weight in preparations for parenteral use and between 1–50% by weight in preparations for oral administration.

In the preparation of pharmaceutical formulations in form of dosage units for oral administration the optically pure compound may be mixed with a solid, powdered carrier, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivates, gelatin or another suitable carrier, stabilizing substances such as alkaline compounds e.g. carbonates, hydroxides and oxides of sodium, potassium, calcium, magnesium and the like as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethyleneglycol waxes. The mixture is then processed into granules or pressed into tablets. Granules and tablets may be coated with an enteric coating which protects the active compound from acid catalyzed degradation as long as the dosage form remains in the stomach. The enteric coating is chosen among pharmaceutically acceptable enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers and the like, if preferred in combination with a suitable plasticizer. To the coating various dyes may be added in order to distinguish among tablets or granules with different amounts of the active compound present.

Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Soft gelatine capsules may also be enteric-coated as described above.

Hard gelatine capsules may contain granules or enteric-coated granules of the active compound. Hard gelatine capsules may also contain the active compound in combination with a solid powdered carrier such as lactose, saccharose, sorbitol, mannitol, potato starch, amylopectin, cellulose derivates or gelatin. The capsules may be enteric-coated as described above.

Dosage units for rectal administration may be prepared in the form of suppositories which contain the active substance mixed with a neutral fat base, or they may be prepared in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules, or they

6

may be prepared in the form of a ready-made micro enema, or they may be prepared in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

Liquid preparation for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing from 0.2% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and/or polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations for oral administration may also be prepared in the form of dry powder to be reconstituted with a suitable solvent prior to use.

Solutions for parenteral administrations may be prepared as solutions of the optically pure compounds of the invention in pharmaceutically acceptable solvents, preferably in a concentration from 0.1 to 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may be manufactured in different unit dose ampoules or vials. Solutions for parenteral administration may also be prepared as dry preparations to be reconstituted with a suitable solvent extemporaneously before use.

The typical daily dose of the active compound will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.

The invention is illustrated by the following examples using preferred procedures for the preparation of optically pure sodium salts and magnesium salts.

The processes described below for optically pure enantiomeric sodium salts of omeprazole result in change of directions from (–) to (+) optical rotation and, vice versa, from (+) to (–) optical rotation when preparing the sodium salt from the neutral form of omeprazole and again, when preparing the magnesium salt from the sodium salt of omeprazole.

EXAMPLE 1

Preparation of (+)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt

100 mg (0.3 mmol) of (–)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole (contaminated with 3% of the (+)-isomer) was dissolved in 1 ml of 2-butanone with stirring. 60 µl of an aqueous solution of 5.0 M sodium hydroxide and 2 ml of toluene were added. The resultant mixture was non-homogeneous. In order to obtain a clear solution, more 2-butanone was added (ca 1 ml) and the mixture was stirred at ambient temperature over night. The formed precipitate was filtered off and washed with ether. There was obtained 51 mg (46%) of the title compound as white crystals m.p. (decomposition) 246–248° C. The optical purity (e.e.) which was analyzed by chiral column chromatography was >99.8%. [α]_D²⁰=+42.8' (concentration, c=0.5%, water).

NMR data are given below.

EXAMPLE 2

Preparation of (–)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt

100 mg-(0.3 mmol) of (+)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-

US 6,875,872 B1

7

benzimidazole (contaminated with 3% of the (-)-isomer) was dissolved in 1 ml of 2-butanone with stirring. 60 μ l of an aqueous solution of 5.0 M sodium hydroxide and 2 ml of toluene were added. The resultant mixture was non-homogeneous. In order to obtain a clear solution, more 2-butanone was added (ca 1 ml) and the mixture was stirred at ambient temperature over night. The formed precipitate was filtered off and washed with ether. There was obtained 56 mg (51%) of the title compound as white crystals m.p. (decomposition) 247–249° C. The optical purity (e.e.) which was analyzed by chiral column chromatography was >99.8%. $[\alpha]_D^{20} = -44.1^\circ$ ($c=0.5\%$, water).

NMR data are given below.

EXAMPLE 3

Preparation of (+)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt

2.9 ml of a 0.1 M solution of NaOH was added to 0.10 g (0.29 mmol) (+)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. To this mixture 2 ml methylene chloride was added, and after mixing in a separatory funnel the aqueous solution was separated off. A solution of 14 mg (0.145 mmol) MgCl₂ in water was added dropwise. The formed precipitate was isolated by centrifugation, and 52 mg (50%) of the product was isolated as an amorphous powder. The optical purity (e.e.) was 98%, and thus the same as the starting material. The optical purity was determined by chromatography on an analytical chiral column. $[\alpha]_D^{20} = +101.20$ ($c=1\%$, methanol). The Mg content of the sample was found to be 3.0%, shown by atomic absorption spectroscopy.

EXAMPLE 4

Preparation of (+)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt

(-)5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt (0.500 g, 1.36 mmol) was dissolved in water (10 ml). To this mixture 10 ml of an aqueous solution of MgCl₂·xH₂O (138 mg, 0.68 mmol) was added dropwise and the formed precipitate was isolated by centrifugation. There was obtained 418 mg (86%) of the product as a white powder. The optical purity (ee) of the product was 99.8% which was the same as the optical purity of the starting material. The optical purity was determined by chromatography on an analytical chiral column. $[\alpha]_D^{20} = +129.9^\circ$ ($c=1\%$, methanol).

EXAMPLE 5

Preparation of (-)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt

(+)5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt (0.165 g, 0.45 mmol) was dissolved in water (3 ml). To this mixture 2 ml of an aqueous solution of MgCl₂·xH₂O (46 mg, 0.23 mmol) was added dropwise and the formed precipitate was isolated by centrifugation. There was obtained 85 mg (51%) of the product as a white powder. The optical purity (ee) of the product was 99.9% which was the same or better as the optical purity of the starting material. The optical purity was determined by chromatography on an analytical chiral column. $[\alpha]_D^{20} = -128.2^\circ$ ($c=1\%$, methanol).

8

TABLE 1

Ex.	Solvent	NMR data δ ppm
5	DMSO-d ₆	2.20(s, 3H), 2.22(s, 3H), 3.69(s, 3H), 3.72(s, 3H), 500 MHz 4.37(d, 1H), 4.75(d, 1H), 6.54(dd, 1H), 6.96(d, 1H), 7.30(d, 1H), 8.21(s, 1H).
10	DMSO-d ₆	2.20(s, 3H), 2.22(s, 3H), 3.69(s, 3H), 3.72(s, 3H), 500 MHz 4.38(d, 1H), 4.73(d, 1H), 6.54(dd, 1H), 6.96(d, 1H), 7.31(d, 1H), 8.21(s, 1H).

A preferred method for preparing optically pure omeprazole enantiomer crystal salts of magnesium is described in Examples 6 and 7.

15

EXAMPLE 6

Enhancement of the Optical Purity by Preparing the Magnesium Salt of (-)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole in Nonaqueous Solution Followed by Crystallization of said Salt

Magnesium (0.11 g, 4.5 mmol) was dissolved and reacted with methanol (50 ml) at 40° C. with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90%(-)-isomer and 10%(+)-isomer] of 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2 mmol) was added to the magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts. After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (+)-isomer), with an optical purity (enantiomeric excess, e.e.) of 80%. This mixture was diluted with acetone (100 ml) and after stirring at room temperature for 15 minutes, a white precipitate was obtained. Additional stirring for 15 minutes and thereafter filtration afforded 1.3 g (50%) of the title compound as white crystals. Chiral analyses of the crystals and mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the crystals and mother liquor was found to be 98.4 e.e. and 64.4% e.e., respectively. Thus, the optical purity (e.e.) has been enhanced from 80% to 98.4% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The product was crystalline as shown by powder X-ray diffraction and the magnesium content was 3.44% as shown by atomic absorption spectroscopy. $[\alpha]_D^{20} = -131.5^\circ$ ($c=0.5\%$, methanol).

55

EXAMPLE 7

Enhancement of the Optical Purity by Preparing the Magnesium Salt of (+)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole in Nonaqueous Solution Followed by Crystallization of said Salt

Magnesium (0.11 g, 4.5 mmol) was dissolved and reacted with methanol (50 ml) at 40° C. with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90%(+)-isomer and 10%(-)-isomer] of 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)

US 6,875,872 B1

9

methyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2 mmol) was added to the magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts. After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (-)-isomer), with an optical purity (e.e.) of 80%. This mixture was diluted with acetone (100 ml) and after stirring at room temperature for one hour, a white precipitate was obtained. Additional stirring for 30 minutes and thereafter filtration afforded 0.35 g of the title compound as white crystals. Additional stirring of the mother liquor for 24 hours at room temperature afforded another 1.0 g (total yield=52%). Chiral analyses of the crystals and the second mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the two crystal fractions was 98.8% e.e. and 99.5% e.e., respectively. The optical purity of the mother liquor was found to be 57% e.e. Thus, the optical purity (e.e.) has been enhanced from 80% to approximately 99% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The first precipitation was crystalline as shown by powder X-ray diffraction and the magnesium content of the same fraction was 3.49% as shown by atomic absorption spectroscopy. $[\alpha]_D^{20} = -135.60^\circ$ (c=0.5%, methanol).

The crystalline salt according to Example 6 is most preferred.

Preparation of the synthetic intermediates according to the invention is described in the following examples.

EXAMPLE 8

Preparation of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(R*-mandeloyloxymethyl]-1H-benzimidazole

A solution of 3.4 g sodium hydroxide in 40 ml water was added to a mixture of 14.4 g (42 mmol) tetrabutylammonium hydrogen sulfate and 6.4 g (42 mmol) (*R*)-(–)-mandelic acid. The mixture was extracted with 400 ml chloroform. After separation, the organic extract was heated to reflux with 16.6 g (42 mmol) of the racemate of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[chloromethyl]-1H-benzimidazole. Evaporation of the solvent was followed by dilution with 100 ml dichloromethane and 700 ml ethyl acetate. The mixture was washed with 3×200 ml water and the organic solution was dried over $MgSO_4$ and then evaporated. The crude material was purified by recrystallization from 100 ml acetonitrile, giving 8.1 g of the title compound (38%) as a diastereomeric mixture.

NMR data are given below.

EXAMPLE 9

Separation of the more Hydrophilic Diastereomer of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(R*-mandeloyloxymethyl]-1H-benzimidazole

The diastereomers of the title compound in Example 8 were separated using reversed phase chromatography (HPLC). Approximately 300 mg of the diastereomeric mixture was dissolved in 10 ml hot acetonitrile which was diluted with 10 ml of a mixture of aqueous 0.1 M ammoniumacetate and acetonitrile (70/30). The solution was injected to the column and the compounds were eluted with

10

a mixture of aqueous 0.1 M ammoniumacetate and acetonitrile (70/30). The more hydrophilic isomer was easier to obtain pure than the less hydrophilic one. The work up procedure for the fraction which contained pure isomer was as follows; extraction with dichloromethane, washing the organic solution with aqueous 5% sodium hydrogen carbonate solution, drying over Na_2SO_4 and evaporation of the solvent on a rotavapor (at the end of the evaporation the removal of acetonitrile was facilitated by adding more dichloromethane). Using 1.2 g of the diastereomeric mixture with the above mentioned technique, the more hydrophilic isomer, 410 mg, was obtained in a pure state as a colorless syrup.

NMR data are given below.

EXAMPLE 10

Preparation of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(S*-mandeloyloxymethyl]-1H-benzimidazole

The product was obtained from 8.1 g (202 mmol) sodium hydroxide in 100 ml water, 34.4 g (101 mmol) tetrabutylammonium hydrogen sulfate, 15.4 g (101 mmol) (*S*)-(+) mandelic acid and 39.9 g (101 mmol) of the racemate of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[chloromethyl]-1H-benzimidazole using the same procedure as in Example 8. Recrystallization from 100 ml acetonitrile yielded 21.3 g, i.e. 41% of the title compound as a diastereomeric mixture.

NMR data are given below.

EXAMPLE 11

Separation of the more hydrophilic diastereomer of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(S*-mandeloyloxymethyl]-1H-benzimidazole

The diastereomers of the title compound in Example 10 were separated using reversed phase chromatography (HPLC) in the same way as in Example 7, but using the diastereomeric mixture of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-*(R/S*)-sulfinyl]-1-[*(S*-mandeloyloxymethyl]-1H-benzimidazole instead of the (*R*)-mandelic ester used in Example 9. Using 2.1 g of the diastereomeric mixture, the more hydrophilic isomer, 760 mg, was obtained in a pure state as a colorless syrup.

NMR data are given below.

EXAMPLE 12

Preparation of (-)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole

0.23 g (0.45 mmol) of the more hydrophilic diastereomer of 6-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[*(R*-mandeloyloxymethyl]-1H-benzimidazole was dissolved in 15 ml methanol. A solution of 36 mg (0.9 mmol) sodium hydroxide in 0.45 ml water was added, and after 10 minutes the mixture was evaporated on a rotavapor. The residue was partitioned between 15 ml water and 15 ml dichloromethane. The organic solution was extracted with 15 ml water and to the combined aqueous solutions was added 85 μ L (1.4 mmol) methyl formate. After 15 minutes the mixture was extracted with 3×10 ml dichloromethane. The organic solution was dried over Na_2SO_4 and then evaporated. There was obtained 0.12 g (77%) of the

US 6,875,872 B1

11

title compound as a colorless syrup. The optical purity (e.e.) which was analyzed by chiral column chromatography was 94%. $[\alpha]_D^{20} = -155^\circ$ (c=0.5%, chloroform).

NMR data are given below

EXAMPLE 13

Preparation of (+)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole

0.76 g (1.5 mmol) of the more hydrophilic diastereomer of 6-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-[*(S*)-mande loxymethyl]-1H-benzimidazole was dissolved in 50 ml methanol. A solution of 0.12 mg (3.0 mmol) sodium hydroxide in 1.5 ml water was added, and after 10 minutes the mixture was evaporated on a rotavapor. The residue was partitioned between 25 ml water and 25 ml dichloromethane. The organic solution was extracted with 25 ml water and to the combined aqueous solutions was added 200 μ l (3.2 mmol) methyl formate. After 15 minutes the mixture was extracted with 3x25 ml dichloromethane. The organic solution was dried over Na_2SO_4 and then evaporated. There was obtained 0.42 g (81%) of the title compound as a colorless syrup. The optical purity (e.e.) which was analyzed by chiral column chromatography was 98%. $[\alpha]_D^{20} = +157^\circ$ (c=0.5%, chloroform). NMR data are given below

TABLE 2

Ex.	Solvent	NMR data δ ppm
8.	CDCl_3 500 MHz	2.18(s, 3H), 2.20(s, 3H), 2.36(s, 3H), 2.39(s, 3H), 3.77(s, 3H), 3.78(s, 3H), 3.82(s, 3H), 3.87(s, 3H), 4.80(d, 1H), 4.88(d, 1H), 5.0(m, 2H), 5.34(s, 2H), 6.43(d, 1H), 6.54(d, 1H), 6.6-6.7(m, 2H), 6.90(d, 1H), 6.95-6.98(m, 2H), 7.01(d, 1H), 7.2-7.3(m, 6H), 7.37(m, 2H), 7.44(m, 2H), 7.58(d, 1H), 7.62(d, 1H), 7.95(s, 1H), 7.97(s, 1H).
9.	CDCl_3 500 MHz	2.20(s, 3H), 2.36(s, 3H), 3.78(s, 3H), 3.82(s, 3H), 4.80(d, 1H), 5.00(d, 1H), 5.35(d, 1H), 6.43(d, 1H), 6.63(d, 1H), 6.90(d, 1H), 6.97(dd, 1H), 7.2-7.3(m, 3H), 7.37(m, 2H), 7.62(d, 1H), 7.97(s, 1H).
10.	CDCl_3 500 MHz	2.19(s, 3H), 2.20(s, 3H), 2.36(s, 3H), 2.39(s, 3H), 3.77(s, 3H), 3.78(s, 3H), 3.83(s, 3H), 3.87(s, 3H), 4.80(d, 1H), 4.88(d, 1H), 5.0(m, 2H), 5.34(s, 2H), 6.43(d, 1H), 6.54(d, 1H), 6.6-6.7(m, 2H), 6.90(d, 1H), 6.96-6.98(m, 2H), 7.01(d, 1H), 7.2-7.3(m, 6H), 7.37(m, 2H), 7.44(m, 2H), 7.58(d, 1H), 7.62(d, 1H), 7.95(s, 1H), 7.97(s, 1H).
11.	CDCl_3 500 MHz	2.20(s, 3H), 2.36(s, 3H), 3.78(s, 3H), 3.82(s, 3H), 4.80(d, 1H), 5.00(d, 1H), 5.35(d, 1H), 6.43(d, 1H), 6.63(d, 1H), 6.90(d, 1H), 6.97(dd, 1H), 7.2-7.3(m, 3H), 7.37(m, 2H), 7.62(d, 1H), 7.97(s, 1H).
12.	CDCl_3 300 MHz	2.18(s, 3H), 2.22(s, 3H), 3.68(s, 3H), 3.83(s, 3H), 4.77(m, 2H), 6.93(dd, 1H), ~7.0(b, 1H), ~7.5(b, 1H), 8.19(s, 1H).
13.	CDCl_3	2.21(s, 3H), 2.23(s, 3H), 3.69(s, 3H), 3.84(s, 3H), 4.76(m, 2H), 6.94(dd, 1H), ~7.0(b, 1H), ~7.5(b, 1H), 8.20(s, 1H).

Pharmaceutical preparations containing the compounds of the invention as active ingredient are illustrated in the following formulations.

Syrup

A syrup containing 1% (weight per volume) of active substance was prepared from the following ingredients:

Compound according to Example 1	1.0 g
Sugar, powder	30.0 g

65

12

-continued

5	Saccharine	0.6 g
	Glycerol	5.0 g
	Flavoring agent	0.05 g
	Ethanol 96%	5.0 g
	Distilled water q.s. to a final volume of	100 ml

10 Sugar and saccharine were dissolved in 60 g of warm water. After cooling the active compound was added to the sugar solution and glycerol and a solution of flavoring agents dissolved in ethanol were added. The mixture was diluted with water to a final volume of 100 ml.

15 Enteric-Coated Tablets
An enteric coated tablet containing 50 mg of active compound was prepared from the following ingredients:

20	Compound according to Example 6 as Mg salt	500 g
	Lactose	700 g
	Methyl cellulose	6 g
	Polyvinylpyrrolidone cross-linked	50 g
	Magnesium stearate	15 g
	Sodium carbonate	6 g
	Distilled water	q. s.
	Cellulose acetate phthalate	200 g
	Cetyl alcohol	15 g
	Isopropanol	2000 g
	Methylene chloride	2000 g

30 Compound according to Example 6, powder, was mixed with lactose and granulated with a water solution of methyl cellulose and sodium carbonate. The wet mass was forced through a sieve and the granulate dried in an oven. After drying the granulate was mixed with polyvinylpyrrolidone and magnesium stearate. The dry mixture was pressed into tablet cores (10 000 tablets), each tablet containing 50 mg of active substance, in a tabletting machine using 7 mm diameter punches.

40 A solution of cellulose acetate phthalate and cetyl alcohol in isopropanol/methylene chloride was sprayed onto the tablets I in an Accela Cota^R, Manesty coating equipment. A final tablet weight of 110 mg was obtained.

Solution for Intravenous Administration

45 A parenteral formulation for intravenous use, containing 4 mg of active compound per ml, was prepared from the following ingredients:

50	Compound according to Example 2	4 g
	Sterile water to a final volume of	1000 ml

55 The active compound was dissolved in water to a final volume of 1000 ml. The solution was filtered through a 0.22 μ m filter and immediately dispensed into 10 ml sterile ampoules. The ampoules were sealed.

Capsules

60 Capsules containing 30 mg of active compound were prepared from the following ingredients:

Compound according to Example 6	300 g
Lactose	700 g
Microcrystalline cellulose	40 g
Hydroxypropyl cellulose low-substituted	62 g

US 6,875,872 B1

13

-continued

Disodium hydrogen phosphate	2 g
Purified water	q. s.

The active compound was mixed with the dry ingredients and granulated with a solution of disodium hydrogen phosphate. The wet mass was forced through an extruder and spheronized and dried in a fluidized bed dryer.

500 g of the pellets above were first coated with a solution of hydroxypropyl methylcellulose, 30 g, in water, 750 g, using a fluidized bed coater. After drying, the pellets were coated with a second coating as given below:

Coating Solution:

Hydroxypropyl methylcellulose phthalate	70 g
Cetyl alcohol	4 g
Acetone	200 g
Ethanol	600 g

The final coated pellets were filled into capsules.
Suppositories

Suppositories were prepared from the following ingredients using a welding procedure. Each suppository contained 40 mg of active compound.

Compound according to Example 1	4 g
Witepsol H-15	180 g

The active compound was homogenously mixed with Witepsol H-15 at a temperature of 41° C. The molten mass was volume filled into pre-fabricated suppository packages to a net weight of 1.84 g. After cooling the packages were heat sealed. Each suppository contained 40 mg of active compound.

Stability Towards Racemization at Different pH Values

The stability of the optically pure compounds of the invention against racemization has been measured at low concentrations in a refrigerator in aqueous buffer solutions at pH 8, 9.3, 10 and 11.2. The stereochemical stability was measured by comparing the optical purity for the (-)-isomer of 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in buffer solution immediately after dissolving and after several days. The measurement was performed by chromatography on an analytical chiral column. The surprising high stereochemical stability

14

in alkaline conditions for the compounds of invention is exemplified by the fact that no racemization for the test compound was obtained at pH 11.2 even after 21 days. At pH 8, 9.3 and 10, the chemical degradation of the compound is more apparent which makes the racemization measurement more difficult to perform, however at none of these pH values a detectable racemization was obtained after 16 days.

In another racemization experiment with the optically pure compounds of the invention, an aqueous phosphate buffer solution (pH=11) of the (+)-isomer of 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt ($c=10^{-5}$ M) was warmed for 26 hours at 37° C. without any racemization at all being observed.

What is claimed is:

1. Magnesium salt of (-)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in an optical purity of at least about 94% enantiomeric excess.
2. The compound according to claim 1, when the optical purity is at least 94% enantiomeric excess.
3. The compound according to claim 1 or 2, wherein the compound is in crystalline form.
4. Magnesium salt of (-)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in an optical purity of at least about 98.4% enantiomeric excess.
5. The compound according to claim 4, wherein the optical purity is at least 98.4% enantiomeric excess.
6. The compound according to claim 4 or 5, wherein the compound is in crystalline form.
7. Magnesium salt of (-)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in an optical purity of at least about 99.8% enantiomeric excess.
8. The compound according to claim 7, wherein the optical purity is at least 99.8% enantiomeric excess.
9. The compound according to claim 7 or 8, wherein the compound is in crystalline form.
10. Magnesium salt of (-)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole in an optical purity of at least about 99.9% enantiomeric excess.
11. The compound according to claim 10, wherein the optical purity is at least 99.9% enantiomeric excess.
12. The compound according to claim 10, wherein the compound is in crystalline form.

* * * * *

EXHIBIT C



US006369085B1

(12) **United States Patent**
Cotton et al.

(10) **Patent No.:** US 6,369,085 B1
(45) **Date of Patent:** Apr. 9, 2002

(54) **FORM OF S-OMEPRAZOLE**

- (75) Inventors: **Hanna Cotton; Anders Kronström; Anders Mattson; Eva Möller**, all of Södertälje (SE)
- (73) Assignee: **AstraZeneca AB**, Sodertalje (SE)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/077,719**(22) PCT Filed: **May 5, 1998**(86) PCT No.: **PCT/SE98/00974**§ 371 Date: **Jun. 8, 1998**§ 102(c) Date: **Jun. 8, 1998**(87) PCT Pub. No.: **WO98/54171**PCT Pub. Date: **Dec. 3, 1998**(30) **Foreign Application Priority Data**

May 30, 1997 (SE) 9702065

(51) Int. Cl.⁷ **A61K 31/4439; C07D 401/12**(52) U.S. Cl. **514/338; 546/273.7**

(58) Field of Search 514/338; 546/273.7

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 4,738,974 A * 4/1988 Brandstrom 514/338
5,530,160 A * 6/1996 Nore et al. 562/571
5,690,960 A * 11/1997 Bengtsson et al. 514/338
5,693,818 A * 12/1997 Vion Unge 514/338
5,714,504 A * 2/1998 Lindberg et al. 514/338
5,877,192 A 3/1999 Lindberg et al. 514/338
5,900,424 A * 5/1999 Kallstrom et al. 514/338

FOREIGN PATENT DOCUMENTS

CN	1136564	11/1996
EP	0005129	10/1979
EP	0124495	11/1984
EP	0247983	12/1987
WO	9427988	12/1994
WO	WO 95/01977	* 1/1995
WO	9601623	1/1996
WO	9602535	2/1996

OTHER PUBLICATIONS

Japanese Chemical Society, Experimental Chemical Seminar, vol. 18, p. 55 (translation), 1958.*

An Introduction to Crystal Chemistry by Evans Cambridge At the Univ. Press. 1964.*

von Unge, S. et al. "Stereochemical assignment of the enantiomers of omeprazole from X-ray analysis of a fenchylolymethyl derivative of (+)-(R)-omeprazole", *Tetrahedron Asymmetry*, vol. 8, No. 12, pp. 1967-1970 (1997).

* cited by examiner

Primary Examiner—Jane Fan

(74) Attorney, Agent, or Firm—White & Case LLP

(57) **ABSTRACT**

The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfanyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.


12 Claims, 5 Drawing Sheets

U.S. Patent

Apr. 9, 2002

Sheet 1 of 5

US 6,369,085 B1




U.S. Patent

Apr. 9, 2002

Sheet 2 of 5

US 6,369,085 B1




U.S. Patent

Apr. 9, 2002

Sheet 3 of 5

US 6,369,085 B1




U.S. Patent

Apr. 9, 2002

Sheet 4 of 5

US 6,369,085 B1




U.S. Patent

Apr. 9, 2002

Sheet 5 of 5

US 6,369,085 B1



US 6,369,085 B1

1**FORM OF S-OMEPRAZOLE**

This application is a 371 of PCT/SE98/00974, May 5, 1998 now WO 9854171 Dec. 3, 1998.

FIELD OF THE INVENTION

The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to intermediates used in the process, and their preparation.

BACKGROUND OF THE INVENTION AND PRIOR ART

The compound 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, having the generic name omeprazole, and therapeutically acceptable salts thereof, are described in EP 5129. The specific alkaline salts of omeprazole are disclosed in EP 124 495. Omeprazole is a proton pump inhibitor, i.e. effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for prevention and treatment of gastric-acid related diseases in mammals and especially in man.

Omeprazole is a sulfoxide and a chiral compound, wherein the sulfur atom being the stereogenic center. Thus, omeprazole is a racemic mixture of its two single enantiomers, the R and S-enantiomer of omeprazole, herein referred to as R-omeprazole and S-omeprazole. The absolute configurations of the enantiomers of omeprazole have been determined by an X-ray study of an N-alkylated derivative of the (+)-enantiomer in non-salt form. The (+)-enantiomer of the non-salt form and the (-)-enantiomer of the non-salt form were found to have R and S configuration, respectively, and the (+)-enantiomer of the magnesium salt and the (-)-enantiomer of the magnesium salt were also found to have R and S configuration, respectively. The conditions for the optical rotation measurement for each of these enantiomers are described in WO 94/27988.

Certain salts of single enantiomers of omeprazole and their preparation are disclosed in WO 94/27988. These compounds have improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation.

WO 96/02535 discloses a process for the preparation of the single enantiomers of omeprazole and salts thereof, and WO 96/01623 discloses a suitable tableted dosage forms of for instance magnesium salts of R- and S-omeprazole.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a X-ray powder diffractogram of the magnesium salt of S-omeprazole trihydrate prepared according to the present invention.

FIG. 2 shows a X-ray powder diffractogram of the potassium salt of S-omeprazole prepared and used in the present application (See examples 2 and 3)

FIG. 3 shows a X-ray powder diffractogram of a magnesium salt of S-omeprazole dihydrate prepared and used in the present application (See example 5)

FIG. 4 shows a X-ray powder diffractogram of a magnesium salt of S-omeprazole dihydrate which is a polymorph

2

of the dihydrate shown in FIG. 3 (See Example 6). This magnesium salt of S-omeprazole dihydrate has been prepared and can be used in the preparation of the magnesium salt of S-omeprazole trihydrate according to the present invention.

FIG. 5 shows X-ray powder diffractogram of the magnesium salt of S-omeprazole prepared according to example A in WO 96/01623.

DESCRIPTION OF THE INVENTION

It has surprisingly been found that the magnesium salt of S-omeprazole occurs in a number of structurally different forms. It is an object of the present invention to provide a substantially pure magnesium salt of S-omeprazole trihydrate, hereinafter referred to as the compound of the invention. This trihydrate can be obtained as a well defined compound. The present invention also provides a process to obtain and a method of differentiating the magnesium salt of S-omeprazole trihydrate from other forms of magnesium salts of S-omeprazole.

The compound of the invention is advantageous because it is more stable than the corresponding magnesium salt compounds in prior art and is therefore easier to handle and store. The compound of the invention is also easier to characterize because it exists in a well defined state. Additionally, the compound of the invention is easier to synthesize in a reproducible manner and thereby easier to handle in a full scale production.

The magnesium salt of S-omeprazole trihydrate obtained according to the present invention is substantially free from magnesium salts of R-omeprazole. The magnesium salt of S-omeprazole trihydrate obtained according to the present invention is also substantially free from other forms of magnesium salts of S-omeprazole, such as the corresponding magnesium salt compounds described in prior art, and dihydrates used in the preparation of the trihydrate compound according to the present invention.

The compound of the invention is characterized by the positions and intensities of the major peaks in the X-ray powder diffractogram, but may also be characterized by conventional FT-IR spectroscopy. These characteristics are not exhibited by any other form of magnesium salt of S-omeprazole and accordingly, the magnesium salt of S-omeprazole trihydrate is easily distinguishable from any other crystal form of the magnesium salt of S-omeprazole disclosed in prior art. The compound of the invention is characterized by being highly crystalline, i.e. having a higher crystallinity than any other form of magnesium salt of S-omeprazole disclosed in the prior art. With the expression "any other form" is meant anhydrides, hydrates, solvates, and polymorphs or amorphous forms thereof disclosed in the prior art. Examples of any other forms of magnesium salt of S-omeprazole includes, but are not limited to, anhydrides, monohydrates, dihydrates, sesquihydrates, trihydrates, alcoholates, such as methanolates and ethanolates, and polymorphs or amorphous forms thereof.

The compound of the invention may also be characterized by its unit cell.

In a further aspect, the present invention provides processes for the preparation of the magnesium salt of S-omeprazole trihydrate which comprises;

- a) treating a magnesium salt of S-omeprazole of any form, for example prepared according to procedures known in the art such as Example A in WO 96/01623 which is incorporated herein by reference, with water at a suitable temperature for a suitable time. By a suitable

US 6,369,085 B1

3

temperature is meant a temperature which induces the transformation of starting material to product without decomposing any of these compounds. Examples of such suitable temperatures include, but are not limited to, room temperature and above. By a suitable time is meant a time that results in high conversion of the starting material into product without causing any decomposition of either compounds, i.e. results in a good yield. This suitable time will vary depending on the temperature used in a way well known to people in the art. The higher the temperature, the shorter time is needed to give the desired conversion. The amount of water is not crucial and will depend on the process conditions used. The magnesium salt of S-omeprazole trihydrate is thereafter separated from the aqueous slurry, for example by filtration or centrifugation and thereafter dried to constant weight; or

b) oxidizing 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole, with an oxidizing agent and a chiral titanium complex, optionally in the presence of a base. The oxidation is carried out in an organic solvent, for example toluene or dichloromethane.

The crude product is converted to the corresponding potassium salt by treatment with a potassium source, such as methanolic potassium hydroxide or methanolic potassium methylate, followed by isolation of the formed salt.

The resulting potassium salt of S-omeprazole is thereafter converted to the corresponding magnesium salt by treatment with a magnesium source, such as magnesium sulfate in a lower alcohol, such as methanol. The solution is optionally filtered and the precipitation is initialized by addition of a non-solvent such as acetone. The product is filtered off and optionally washed with water and further processed as is described in a) above. Alternatively, the potassium salt may be treated with a magnesium source, such as magnesium sulfate in water, and isolation of the magnesium salt of S-omeprazole trihydrate, or any other conventional technique for transforming a potassium salt to the corresponding magnesium salt can be used and is within the scope of the present invention.

Yet a further aspect of the present invention is to provide a suitable intermediate used in the preparation of the compound of the invention, as well as a process for its preparation. The potassium salt of S-omeprazole is found to be such a suitable intermediate. The potassium salt of S-omeprazole may also be used as an active component of a pharmaceutical formulation to be used in the treatment of gastrointestinal diseases.

The compound of the invention, i.e. the magnesium salt of S-omeprazole trihydrate, prepared according to the present invention may be analyzed by XRPD, a technique which is known per se.

The amount of water in the magnesium salt of S-omeprazole trihydrate is determined by thermogravimetric analysis, a technique which is known per se.

The compound of the invention is effective as a gastric acid secretion inhibitor, and is useful as an antiulcer agent. In a more general sense, it can be used for prevention and treatment of gastric-acid related conditions in mammals and especially in man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, it may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. The com-

4

pound of the invention may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to prevent aspiration of gastric acid and to prevent and treat stress ulceration. Further, the compound of the invention may be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections and diseases related to these. The compound of the invention may also be used for treatment of inflammatory conditions in mammals, including man.

Any suitable route of administration may be employed for providing the patient with an effective dosage of the magnesium salt of S-omeprazole trihydrate, according to the invention. For example, peroral or parenteral formulations and the like may be employed. Dosage forms include capsules, tablets, dispersions, suspensions and the like.

It is further provided a pharmaceutical composition comprising the magnesium salt of S-omeprazole trihydrate according to the invention, as active ingredient, in association with a pharmaceutically acceptable carrier, diluent or excipient and optionally other therapeutic ingredients. Compositions comprising other therapeutic ingredients are especially of interest in the treatment of Helicobacter infections. The invention also provides the use of the magnesium salt of S-omeprazole trihydrate of the invention in the manufacture of a medicament for use in the treatment of a gastric-acid related condition and a method of treating a gastric-acid related condition which method comprises administering to a subject suffering from said condition a therapeutically effective amount of the magnesium salt of S-omeprazole trihydrate according to the invention.

The compositions of the invention include compositions suitable for peroral or parenteral administration. The most preferred route is the oral route. The compositions may be conveniently presented in unit dosage forms, and prepared by any methods known in the art of pharmacy.

In the practice of the invention, the most suitable route of administration as well as the magnitude of a therapeutic dose of the magnesium salt of S-omeprazole trihydrate according to the invention in any given case will depend on the nature and severity of the disease to be treated. The dose, and dose frequency, may also vary according to the age, body weight, and response of the individual patient. Special requirements may be needed for patients having Zollinger-Ellison syndrome, such as a need for higher doses than the average patient. Children and patients with liver diseases generally will benefit from doses that are somewhat lower than the average. Thus, in some conditions it may be necessary to use doses outside the ranges stated below, for example long term treatments may request lower dosage. Such higher and lower doses are within the scope of the present invention. Such daily doses may vary between 5 mg to 300 mg.

In general, a suitable oral dosage form of the compound of the invention may cover a dose range from 5 mg to 300 mg total daily dose, administered in one single dose or equally divided doses. A preferred dosage range is from 10 mg to 80 mg.

The compound of the invention may be combined as the active component in intimate admixture with a pharmaceutical carrier according to conventional techniques, such as the oral formulations described in WO 96/01623 and EP 247 983, the disclosures of which are hereby incorporated as a whole by reference.

Combination preparations comprising the magnesium salt of S-omeprazole trihydrate and other active ingredients may also be used. Examples of such active ingredients include, but are not limited to anti-bacterial compounds, non-steroidal anti-inflammatory agents, antacid agents, alginates and prokinetic agents.

US 6,369,085 B1

5

The examples which follow will further illustrate the preparation of the compound of the invention, according to different process routes and including new intermediates. These examples are not intended to limit the scope of the invention as defined hereinabove or as claimed below.

EXAMPLES

Example 1

S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate

Water (157 kg) was added to the wet crystals of the magnesium salt of S-omeprazole, prepared according to Example 4, below. The mixture was heated to 38° C. with stirring and left for 3 hours. The crystals were filtered off and dried in vacuo. Yield: 31.6 kg

X-ray powder diffraction analysis was performed on a sample of the crystals prepared above according to standard methods, which can be found in e.g. Kitaigorodsky, A. I. (1973), Molecular Crystals and Molecules, Academic Press, New York; Bunn, C. W. (1948), Chemical Crystallography, Clarendon Press, London; or Klug, H. P. & Alexander, L. E. (1974), X-Ray Diffraction Procedures, John Wiley and Sons, New York. The analysis gave the diffractogram depicted in FIG. 1. The main peaks, with positions and relative intensities, have been extracted from the diffractogram in FIG. 1 and is given below in table 1. The relative intensities are less reliable and instead of numerical values the following definitions are used.

% Relative Intensity	Definition
25–100	vs (very strong)
10–25	s (strong)
3–10	m (medium)
1–3	w (weak)
<1	vw (very weak)

Some additional very weak peaks found in the diffractogram have been omitted from table 1.

TABLE 1

Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole trihydrate.

d-value / Å	Relative Intensity
2.67	m
2.79	m
3.27	m
3.52	s
3.82	s
3.96	vs
4.14	m
5.2	m
5.6	m
6.7	vs
6.9	s
8.3	w
16.6	vs

Example 2

S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole potassium salt

A solution of 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole (15.4 g, 46.8 mmol) in toluene (70 ml) was heated to 50° C. and water

6

(0.05 ml, 2.8 mmol) and D-(–)-diethyl tartrate (2.02 g, 9.82 mmol) were added. The reaction mixture was stirred for 20 minutes. Titanium(IV)isopropoxide (1.34 g, 4.68 mmol) was added and the reaction mixture was stirred for 45 minutes.

5 The mixture was cooled to 30° C. and diisopropylethylamine (0.91 g, 7.01 mmol) was added followed by cumene hydroperoxide (9.52 g, 51.89 mmol). The resultant mixture was stirred at 30° C. for 3 hours. Methanol (40 ml) was added followed by potassium hydroxide (3.05 g, 46.8 mmol) 10 in methanol (30 ml). Seed crystals were added and the reaction mixture was stirred at 35° C. overnight. The precipitated product was filtered off, washed with methanol and toluene and dried in vacuo. Yield: 9.74 g (54%).

15

Example 3

S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole potassium salt

Water (157.6 g) was added to a solution of 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole in toluene (370 ml; 211.5 g/l) with a water content of 0.031% (w/w), followed by addition of D-(–)-diethyl tartrate (8.55 ml). The solution was heated to 50° C. and stirred at this temperature for 20 minutes. Titanium(IV) isopropoxide (7.15 ml) was added and reaction was left at 25 50° C. for 45 minutes. The temperature was lowered to 30° C. and diisopropylethylamine (6.2 ml) was added. Cumene hydroperoxide was added at an appropriate speed to maintain the temperature from 28° C. to 34° C. The temperature was raised to 35° C. after 2 hours and potassium methoxide (24.55 g) in methanol (222 ml) was added. The mixture was filtered after 14 hours and the crystals were washed with methanol:toluene (240 ml; 1:1) and methanol (120 ml) and dried. Yield: 79 g (74%), ee>99.9%. $[\alpha]_D^{20} = +28.7^\circ$ (c=1%, water); Assay: 89% is S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole potassium salt (11% is methanol).

1H-NMR (200 MHz, DMSO-d6, δ ppm): 2.23 (s, 3H), 2.24 (s, 3H), 3.71 (s, 3H), 3.75 (s 3H), 4.40 (d, 1H), 4.78 (d, 1H), 6.58 (dd, 1H), 7.00 (d, 1H), 7.35 (d, 1H), 8.25 (s, 1H).

40 The products from Examples 2 and 3 were analysed using X-ray powder diffraction as described in Example 1 and gave the diffractogram depicted in FIG. 2 and given below in

45 Table 2. Some additional very weak peaks found in the diffractogram have been omitted from Table 2.

TABLE 2

Positions and intensities of the major peaks in the XRP-diffractogram of the potassium salt of S-omeprazole.

d-value/Å	Relative intensity	d-value/Å	Relative intensity
13.6	vs	3.52	m
10.6	vw	3.42	w
7.8	m	3.38	w
6.8	m	3.34	m
6.5	m	3.28	w
6.2	w	3.20	m
6.1	m	3.12	w
5.8	s	3.06	w
5.4	m	3.03	w
5.3	w	2.97	w
5.2	w	2.93	vw
5.0	vw	2.89	w
4.75	m	2.85	m
4.71	w	2.76	w
4.52	w	2.71	vw
4.42	w	2.66	vw

$\alpha_1 = 1.54060 \text{ \AA}$

US 6,369,085 B1

7

8

TABLE 2-continued

Positions and intensities of the major peaks in the XRP-diffractogram of the potassium salt of S-omeprazole.

d-value/Å	Relative Intensity	d-value/Å	Relative Intensity
4.32	w	2.58	w
4.27	m	2.57	w
3.98	vw	2.56	w
3.92	w	2.52	vw
3.89	w	2.47	vw
3.87	w	2.45	vw
3.81	w	2.43	vw
3.74	m	2.40	vw
3.60	m	2.38	vw
3.55	m	2.31	vw

Example 4

S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt

Methanol (148 kg) was added to S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole potassium salt (71 kg, methanol content= 13%). MgSO₄×7 H₂O (40 kg) was added to the mixture while stirring. After 70 minutes the mixture was filtered and the filtrate was washed with methanol (46 kg). The solution was concentrated to a volume of 100 liter, acetone (253 kg) was added and the resulting mixture was left for 4 hours. The precipitated product was filtered off, washed with acetone and water. The wet crystals were immediately used as is described in Example 1.

Example 5

S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt dihydrate

5.0 g of the moist product from Example 4 with an approximate dry content of 74%, was dried in vacuum at 35° C. over night to yield 3.58 g (2.68 mmol) of S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt dihydrate, named Form B.

The product was analyzed using X-ray powder diffraction as described in Example 1, and the analyze gave the diffractogram depicted in FIG. 3 and given below in Table 3. Some additional peaks with low intensities found in the diffractogram have been omitted from Table 3.

TABLE 3

Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole dihydrate, Form B.

d-value/Å	Relative Intensity
4.19	m
4.45	m
4.68	m
4.79	s
4.91	s
4.98	s
5.1	m
5.4	s
5.5	m
5.6	m
5.8	m
6.3	m
6.7	s
7.9	m

TABLE 3-continued

5 Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole dihydrate, Form B.

d-value/Å	Relative Intensity
8.1	s
11.0	m
11.8	m
10 14.9	vs

Conversion of magnesium salt of S-omeprazole dihydrate to trihydrate

15 This material was subsequently processed to S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate according to the procedure described for the moist substance in Example 1.

Example 6

20 S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt dihydrate

A methanolic solution of S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt was prepared as is described in Example 4. Such a solution of S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt (1.86 g) in 5 ml methanol was concentrated by evaporation until 1.58 ml methanol remained. Then, a mixture of 1.6 ml water and 6.32 ml aceton was added. The solution was allowed to crystallize during 26 h at room temperature. The resulting crystals were filtered off and dried at 40 °C. under reduced pressure giving 1.17 g of S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt dihydrate, named form A.

The product was analyzed using X-ray powder diffraction as described in Example 1 and gave the diffractogram depicted in FIG. 4 and given below in Table 4. Some additional peaks with low intensities found in the diffractogram have been omitted from Table 4.

TABLE 4

45 Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole dihydrate, Form A.

d-value/Å	Relative Intensity
50 3.04	s
3.14	s
3.18	m
4.05	s
4.19	s
4.32	m
4.54	s
4.69	vs
5.2	s
5.3	s
5.8	s
6.2	vs
6.6	s
60 15.5	vs

Example 7

65 S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate

22.0 g (29.1 mmol) of S-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole

US 6,369,085 B1

9

potassium salt was dissolved in 40 mL of water. The solution was seeded with 0.11 g (0.1 mmol) S-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate. 22 mL (69.6 mmol) of MgSO₄ (aq) was added under a 3 h period. The slurry was filtered off and the precipitate was elutriated in water for approximately 30 minutes and the crystals were filtered off and dried (35° C., vacuum).

Yield: 9.15 g (11.6 mmol; 80%). The substance had a purity (HPLC): 99.8 area %, Mg content: 3.40% (w/w) and ee: 99.8%.

The product was analyzed using X-ray powder diffraction and the result complies with FIG. 1 and Table 1.

Reference Example A
S-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt

(The method used is in accordance with the method described in Example A in WO 96/01623)

Magnesium (0.11 g, 4.5 mmol) was dissolved and reacted with methanol (50 mL) at 40° C. with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90%(-)-isomer and 10%(+)-isomer] of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2 mmol) was added to the magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 mL) was added in order to precipitate inorganic magnesium salts. After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (+)-isomer), with an optical purity (enantiomeric excess, e.e.) of 80%. This mixture was diluted with acetone (100 mL) and after stirring at room temperature for 15 minutes, a white precipitate was obtained. Additional stirring for 15 minutes and thereafter filtration afforded 1.3 g (50%) of the title compound as white crystals. Chiral analyses of the crystals and mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the crystals and mother liquor was found to be 98.4 e.e. and 64.4% e.e., respectively. Thus, the optical purity (ee.) has been enhanced from 80% to 98.4% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The product was crystalline as shown by powder X-ray diffraction and the magnesium content was 3.44% as shown by atomic absorption spectroscopy. $[\alpha]_D^{20} = -131.5^\circ$ (c=0.5%, methanol).

The product was analyzed using X-ray powder diffraction as described in Example 1 and gave the diffractogram depicted in FIG. 5 and given below in Table 5. Some additional very weak peaks found in the diffractograms have been omitted from Table 5.

10

TABLE 5-continued

Positions and intensities of the major peaks in the XRP-diffractogram shown in FIG. 5.

d-value/Å	Relative Intensity
6.8	s
7.8	s
8.4	vs
10.8	s
12.2	s
15.1	vs

What is claimed is:

1. The magnesium salt of S-omeprazole trihydrate, wherein the compound is characterized by the following major peaks in its X-ray diffractogram:

d-value / Å	Relative Intensity
2.67	m
2.79	m
3.27	m
3.52	s
3.82	s
3.96	vs
4.14	m
5.2	m
5.6	m
6.7	vs
6.9	s
8.3	w
16.6	vs

2. The magnesium salt of S-omeprazole trihydrate according to claim 1, wherein the compound is in a highly crystalline form.

3. The magnesium salt of S-omeprazole trihydrate according to claim 1, wherein the compound is in a stable form.

4. A process for the preparation of the magnesium salt of S-omeprazole trihydrate according to any of claims 1, 2 or 3 which comprises treating a magnesium salt of S-omeprazole any other form with water.

5. A process for the preparation of the magnesium salt of S-omeprazole trihydrate according to any of claims 1, 2 or 3 which comprises the following steps:

- mixing a potassium salt of S-omeprazole with an organic solvent;
- converting the potassium salt of S-omeprazole into a corresponding magnesium salt of S-omeprazole by treating the potassium salt with a magnesium source;
- precipitating the magnesium salt of S-omeprazole by addition of a non-solvent;
- isolating the obtained magnesium salt of S-omeprazole;
- treating the obtained magnesium salt of S-omeprazole with water, and
- isolating and drying the obtained magnesium salt of S-omeprazole trihydrate.

6. The process according to claim 5, wherein the organic solvent of step a) is methanol.

7. The process according to claim 5, wherein the non-solvent of step c) is acetone.

8. The process according to claim 5 wherein steps a) to e) are replaced by the following single step: converting the potassium salt of S-omeprazole into a corresponding magnesium salt of S-omeprazole by treating the potassium salt with a magnesium source in water.

US 6,369,085 B1

11

9. The process according to claim 5, wherein the magnesium source is magnesium sulfate.

10. The process according to claim 8, wherein the magnesium source is magnesium sulfate.

11. A pharmaceutical composition comprising the magnesium salt of S-omeprazole trihydrate according to any of claims 1, 2 or 3 as active ingredient and a pharmaceutically acceptable carrier.

12

12. A method of treating a gastric acid related condition which method comprises administering to a subject suffering from said condition a therapeutically effective amount of the magnesium salt of S-omeprazole trihydrate according to any of claims 1, 2 or 3.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,369,085 B1
DATED : April 9, 2002
INVENTOR(S) : Cotton et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,

Item [22] PCT Filed, delete “**May 5, 1998**” and insert therefor -- **May 25, 1998**--.

Column 10,

Line 42, insert -- of -- after “S-omeprazole”.

Signed and Sealed this

Eighth Day of April, 2003



JAMES E. ROGAN
Director of the United States Patent and Trademark Office